Chemical: Prodrug
cyclophosphamide

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


1. FDA Label for cyclophosphamide

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Anemia
    • Adverse reactions section
    • source: PHONT
  • Breast Neoplasms
    • Warnings section, Precautions section
    • source: PHONT
  • Cystitis
    • Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Depression
    • Contraindications section
    • source: PHONT
  • Leukemia
    • Indications & usage section, Warnings section, Precautions section
    • source: PHONT
  • Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Neutropenia
    • Adverse reactions section
    • source: PHONT
  • Thrombocytopenia
    • Adverse reactions section, Precautions section
    • source: PHONT

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for cyclophosphamide

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA CYP2B6 *1 N/A N/A N/A
VIP CA VA CYP2B6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2B6 *6A N/A N/A N/A
VIP No VIP available No VIP available CYP2C19 *2A N/A N/A N/A
VIP No VIP available No VIP available CYP2C19 *3A N/A N/A N/A
No VIP available No VIP available VA CYP2C8 *1A N/A N/A N/A
No VIP available No VIP available VA CYP2C8 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C8 *4 N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2C19 poor metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available VA
CYP2C9 poor metabolizer N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs10035440 NC_000005.10:g.31539356T>C, NC_000005.9:g.31539463T>C, NM_018356.2:c.807+667T>C, NR_134298.1:n.710+667T>C, XM_005248319.1:c.12+667T>C, XM_005248319.2:c.12+667T>C, XM_006714479.1:c.555+667T>C, XM_006714480.2:c.12+667T>C, XM_011514062.1:c.900+667T>C, XR_241704.1:n.934+667T>C, rs13155198, rs56434987, rs58924525, rs59453111
T > C
SNP
No VIP available No Clinical Annotations available VA
rs10061133 NC_000005.10:g.55170716A>G, NC_000005.9:g.54466544A>G, NM_001145734.2:c.126+1872T>C, NM_001170402.1:c.126+1872T>C, NM_152623.2:c.126+1872T>C, NR_029960.1:n.-94T>C, NR_030387.1:n.27T>C, XM_005248450.1:c.126+1872T>C, XM_011543218.1:c.126+1872T>C
A > C
A > T
SNP
No VIP available CA VA
rs10276036 NC_000007.13:g.87180198C>T, NC_000007.14:g.87550882C>T, NG_011513.1:g.167367G>A, NM_000927.4:c.1000-44G>A, rs10488634, rs111193439, rs17276942, rs57688958, rs58206924
C > A
C > T
SNP
No VIP available CA VA
rs1042522 NC_000017.10:g.7579472G=, NC_000017.10:g.7579472G>C, NC_000017.10:g.7579472G>T, NC_000017.11:g.7676154G=, NC_000017.11:g.7676154G>C, NC_000017.11:g.7676154G>T, NG_017013.2:g.16397C=, NG_017013.2:g.16397C>A, NG_017013.2:g.16397C>G, NM_000546.5:c.215C=, NM_000546.5:c.215C>A, NM_000546.5:c.215C>G, NM_001126112.2:c.215C=, NM_001126112.2:c.215C>A, NM_001126112.2:c.215C>G, NM_001126113.2:c.215C=, NM_001126113.2:c.215C>A, NM_001126113.2:c.215C>G, NM_001126114.2:c.215C=, NM_001126114.2:c.215C>A, NM_001126114.2:c.215C>G, NM_001126115.1:c.-939C=, NM_001126115.1:c.-939C>A, NM_001126115.1:c.-939C>G, NM_001126116.1:c.-939C=, NM_001126116.1:c.-939C>A, NM_001126116.1:c.-939C>G, NM_001126117.1:c.-939C=, NM_001126117.1:c.-939C>A, NM_001126117.1:c.-939C>G, NM_001126118.1:c.98C=, NM_001126118.1:c.98C>A, NM_001126118.1:c.98C>G, NM_001276695.1:c.98C=, NM_001276695.1:c.98C>A, NM_001276695.1:c.98C>G, NM_001276696.1:c.98C=, NM_001276696.1:c.98C>A, NM_001276696.1:c.98C>G, NM_001276697.1:c.-1020C=, NM_001276697.1:c.-1020C>A, NM_001276697.1:c.-1020C>G, NM_001276698.1:c.-1020C=, NM_001276698.1:c.-1020C>A, NM_001276698.1:c.-1020C>G, NM_001276699.1:c.-1020C=, NM_001276699.1:c.-1020C>A, NM_001276699.1:c.-1020C>G, NM_001276760.1:c.98C=, NM_001276760.1:c.98C>A, NM_001276760.1:c.98C>G, NM_001276761.1:c.98C=, NM_001276761.1:c.98C>A, NM_001276761.1:c.98C>G, NP_000537.3:p.Pro72=, NP_000537.3:p.Pro72Arg, NP_000537.3:p.Pro72His, NP_001119584.1:p.Pro72=, NP_001119584.1:p.Pro72Arg, NP_001119584.1:p.Pro72His, NP_001119585.1:p.Pro72=, NP_001119585.1:p.Pro72Arg, NP_001119585.1:p.Pro72His, NP_001119586.1:p.Pro72=, NP_001119586.1:p.Pro72Arg, NP_001119586.1:p.Pro72His, NP_001119590.1:p.Pro33=, NP_001119590.1:p.Pro33Arg, NP_001119590.1:p.Pro33His, NP_001263624.1:p.Pro33=, NP_001263624.1:p.Pro33Arg, NP_001263624.1:p.Pro33His, NP_001263625.1:p.Pro33=, NP_001263625.1:p.Pro33Arg, NP_001263625.1:p.Pro33His, NP_001263689.1:p.Pro33=, NP_001263689.1:p.Pro33Arg, NP_001263689.1:p.Pro33His, NP_001263690.1:p.Pro33=, NP_001263690.1:p.Pro33Arg, NP_001263690.1:p.Pro33His, XM_005256778.1:c.176-21C=, XM_005256778.1:c.176-21C>A, XM_005256778.1:c.176-21C>G, XR_243565.1:n.354C=, XR_243565.1:n.354C>A, XR_243565.1:n.354C>G, XR_243566.1:n.354C=, XR_243566.1:n.354C>A, XR_243566.1:n.354C>G, rs17844988, rs17857747, rs17882155, rs2229076, rs3174747, rs4134781, rs60388830
G > C
SNP
P72R
No VIP available No Clinical Annotations available VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs10505168 NC_000008.10:g.113655752T>C, NC_000008.11:g.112643523T>C, NM_052900.2:c.2998+1586A>G, NM_198123.1:c.3310+1586A>G, NM_198124.1:c.3190+1586A>G, NR_031745.1:n.31T>C, XM_005250771.1:c.3190+1586A>G, XM_011516808.1:c.3112+1586A>G, XM_011516809.1:c.2872+1586A>G, XM_011516810.1:c.2800+1586A>G, XM_011516811.1:c.1414+1586A>G, XM_011516812.1:c.3190+1586A>G, XM_011516813.1:c.586+1586A>G, XM_011516814.1:c.3190+1586A>G, XM_011516816.1:c.2998+1586A>G, rs60368931
T > A
T > G
SNP
No VIP available CA VA
rs1051740 NC_000001.10:g.226019633T>C, NC_000001.11:g.225831932T>C, NG_009776.1:g.26837T>C, NM_000120.3:c.337T>C, NM_001136018.3:c.337T>C, NM_001291163.1:c.337T>C, NP_000111.1:p.Tyr113His, NP_001129490.1:p.Tyr113His, NP_001278092.1:p.Tyr113His, XM_005273085.1:c.337T>C, XP_005273142.1:p.Tyr113His, rs16845366, rs17417482, rs1800444, rs2259405, rs3192120, rs52794507, rs59266540
T > C
SNP
Y113H
No VIP available CA VA
rs1052536 NC_000017.10:g.33331575C>T, NC_000017.11:g.35004556C>T, NG_029221.1:g.29059C>T, NM_013975.3:c.*50C>T, XM_005257970.1:c.*50C>T, XM_005257970.2:c.*50C>T, XM_005257971.1:c.*50C>T, XM_011524797.1:c.2823+1767C>T, XM_011524798.1:c.2796+1767C>T, XM_011524799.1:c.2796+1767C>T, XM_011524800.1:c.2823+1767C>T, rs17667663, rs3192959, rs56593019, rs59815732, rs60821611
C > T
SNP
No VIP available CA VA
rs1056836 NC_000002.11:g.38298203C>G, NC_000002.12:g.38071060G=, NG_008386.2:g.10042C=, NG_008386.2:g.10042C>G, NM_000104.3:c.1294C=, NM_000104.3:c.1294C>G, NP_000095.2:p.Leu432=, NP_000095.2:p.Leu432Val, rs17405323, rs3731848, rs52802961, rs59494749
C > G
SNP
L432V
No VIP available CA VA
rs11226 NC_000012.11:g.1021813G>A, NC_000012.12:g.912647G>A, NG_007984.2:g.164589G>A, NG_017078.2:g.82395C>T, NM_001297419.1:c.*744C>T, NM_001297421.1:c.*744C>T, NM_134424.3:c.*744C>T, NR_123713.1:n.2422C>T, XM_005253720.1:c.*744C>T, XM_005253720.3:c.*744C>T, XM_005253721.1:c.*744C>T, XM_005253721.2:c.*744C>T, XM_005253722.1:c.*744C>T, XM_005253723.1:c.*744C>T, XM_011520990.1:c.*744C>T, XM_011520991.1:c.*744C>T, XM_011520992.1:c.*744C>T, XM_011520995.1:c.*744C>T, XR_242986.1:n.2266C>T, XR_931521.1:n.2088C>T, XR_931522.1:n.2163C>T, rs11571479, rs3192069, rs57985635
G > -
G > A
SNP
No VIP available CA VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available No Clinical Annotations available VA
rs1131341 NC_000016.10:g.69714966G>A, NC_000016.9:g.69748869G>A, NG_011504.1:g.16665C>T, NM_000903.2:c.415C>T, NM_001025433.1:c.415C>T, NM_001025434.1:c.304-1837C>T, NM_001286137.1:c.303+3157C>T, NP_000894.1:p.Arg139Trp, NP_001020604.1:p.Arg139Trp, XM_005255830.1:c.303+3157C>T, rs11555214, rs117044374, rs17413734, rs3191186, rs386597012, rs4986998, rs52820907, rs57338209
G > A
SNP
R139W
rs1138272 NC_000011.10:g.67586108C>T, NC_000011.9:g.67353579C>T, NG_012075.1:g.7514C>T, NM_000852.3:c.341C>T, NP_000843.1:p.Ala114Val, XM_005273958.1:c.338C>T, XP_005274015.1:p.Ala113Val, rs11553894, rs17434783, rs1799811, rs1804665, rs3202011, rs4134657, rs52800258, rs61323549
C > T
SNP
A114V
No VIP available CA VA
rs1142345 NC_000006.11:g.18130918T>C, NC_000006.12:g.18130687T>C, NG_012137.2:g.29457A>G, NM_000367.3:c.719A>G, NP_000358.1:p.Tyr240Cys, XM_011514839.1:c.674A>G, XM_011514840.1:c.650A>G, XP_011513141.1:p.Tyr225Cys, XP_011513142.1:p.Tyr217Cys, rs16880254, rs1801205, rs29001646, rs52798150, rs61510596
T > C
SNP
Y240C
No VIP available CA VA
rs1143684 NC_000006.11:g.3010390C>T, NC_000006.12:g.3010156C>T, NG_034013.1:g.15341C>T, NM_000904.4:c.139C>T, NM_001290221.1:c.139C>T, NM_001290222.1:c.139C>T, NM_001318940.1:c.139C>T, NP_000895.2:p.Leu47Phe, NP_001277150.1:p.Leu47Phe, NP_001277151.1:p.Leu47Phe, NP_001305869.1:p.Leu47Phe, XM_005249147.1:c.139C>T, XM_005249148.1:c.139C>T, XM_005249148.2:c.139C>T, XM_005249149.1:c.139C>T, XM_005249149.2:c.139C>T, XM_005249150.1:c.139C>T, XM_005249150.2:c.139C>T, XM_005249151.1:c.139C>T, XM_005249151.3:c.139C>T, XM_005249152.1:c.139C>T, XM_006715100.1:c.139C>T, XM_011514642.1:c.139C>T, XM_011514643.1:c.139C>T, XM_011514644.1:c.139C>T, XM_011514645.1:c.139C>T, XM_011514646.1:c.139C>T, XP_005249204.1:p.Leu47Phe, XP_005249205.1:p.Leu47Phe, XP_005249206.1:p.Leu47Phe, XP_005249207.1:p.Leu47Phe, XP_005249208.1:p.Leu47Phe, XP_005249209.1:p.Leu47Phe, XP_006715163.1:p.Leu47Phe, XP_011512944.1:p.Leu47Phe, XP_011512945.1:p.Leu47Phe, XP_011512946.1:p.Leu47Phe, XP_011512947.1:p.Leu47Phe, XP_011512948.1:p.Leu47Phe, rs17856164, rs2756081, rs60515731
C > T
SNP
L47F
No VIP available CA VA
rs11615 NC_000019.10:g.45420395A>G, NC_000019.9:g.45923653A>G, NG_015839.2:g.63434T>C, NM_001166049.1:c.354T>C, NM_001983.3:c.354T>C, NM_202001.2:c.354T>C, NP_001159521.1:p.Asn118=, NP_001974.1:p.Asn118=, NP_973730.1:p.Asn118=, XM_005258634.1:c.354T>C, XM_005258635.1:c.354T>C, XM_005258635.2:c.354T>C, XM_005258636.1:c.354T>C, XM_005258636.3:c.354T>C, XM_005258637.1:c.354T>C, XM_005258638.1:c.138T>C, XM_011526610.1:c.354T>C, XP_005258691.1:p.Asn118=, XP_005258692.1:p.Asn118=, XP_005258693.1:p.Asn118=, XP_005258694.1:p.Asn118=, XP_005258695.1:p.Asn46=, XP_011524912.1:p.Asn118=, rs1130005, rs17285882, rs17359303, rs17845191, rs17858003, rs17859564, rs2228629, rs3177700, rs3188446, rs3752251, rs59923575
A > G
SNP
N118N
No VIP available CA VA
rs117532069 NC_000020.10:g.53301068G>A, NC_000020.11:g.54684529G>A
G > A
SNP
No VIP available No Clinical Annotations available VA
rs11861115 NC_000016.10:g.16105813G=, NC_000016.10:g.16105813G>A, NC_000016.9:g.16199670G>A, NG_028268.1:g.161237G=, NG_028268.1:g.161237G>A, NM_004996.3:c.2736-925A>G, NM_004996.3:c.2736-925G>A, NT_187607.1:g.1763672A=, NT_187607.1:g.1763672A>G, XM_005255326.1:c.2766-925G>A, XM_005255327.1:c.2610-925G>A, XM_005255328.1:c.2598-925G>A, XM_005255329.1:c.2559-925G>A, XM_011522497.1:c.2712-925A>G, XM_011522497.1:c.2712-925G>A, XM_011522498.1:c.2643-925A>G, XM_011522498.1:c.2643-925G>A
G > A
SNP
No VIP available No Clinical Annotations available VA
rs11866002 NC_000016.10:g.58553833C>T, NC_000016.9:g.58587737C>T, NM_001265612.1:c.2904G>A, NM_016284.4:c.2919G>A, NM_206999.2:c.2919G>A, NP_001252541.1:p.Gln968=, NP_057368.3:p.Gln973=, NP_996882.1:p.Gln973=, NR_049763.1:n.3237G>A, XM_005255845.1:c.2919G>A, XM_005255846.1:c.2919G>A, XM_005255847.1:c.2916G>A, XM_005255848.1:c.2904G>A, XM_005255849.1:c.2916G>A, XM_005255850.1:c.2919G>A, XM_005255851.1:c.2919G>A, XP_005255902.1:p.Gln973=, XP_005255903.1:p.Gln973=, XP_005255904.1:p.Gln972=, XP_005255905.1:p.Gln968=, XP_005255906.1:p.Gln972=, XP_005255907.1:p.Gln973=, XP_005255908.1:p.Gln973=, XR_243400.1:n.3197G>A, rs59053850
C > -
C > T
SNP
Q968Q
No VIP available CA VA
rs12210538 NC_000006.11:g.110760008A>G, NC_000006.12:g.110438805A>G, NM_033125.3:c.1226T>C, NP_149116.2:p.Met409Thr, XM_005267183.1:c.1130T>C, XM_005267184.1:c.716T>C, XM_005267184.2:c.716T>C, XM_005267185.1:c.764T>C, XM_011536204.1:c.1097T>C, XM_011536205.1:c.1226T>C, XM_011536206.1:c.944T>C, XM_011536207.1:c.872T>C, XM_011536208.1:c.836T>C, XM_011536209.1:c.821T>C, XM_011536210.1:c.1184-2844T>C, XM_011536211.1:c.746T>C, XM_011536212.1:c.536T>C, XP_005267240.1:p.Met377Thr, XP_005267241.1:p.Met239Thr, XP_005267242.1:p.Met255Thr, XP_011534506.1:p.Met366Thr, XP_011534507.1:p.Met409Thr, XP_011534508.1:p.Met315Thr, XP_011534509.1:p.Met291Thr, XP_011534510.1:p.Met279Thr, XP_011534511.1:p.Met274Thr, XP_011534513.1:p.Met249Thr, XP_011534514.1:p.Met179Thr, rs17494155, rs386523325
A > G
SNP
M409T
No VIP available CA VA
rs12721655 NC_000019.10:g.41004377A>G, NC_000019.9:g.41510282A>G, NG_007929.1:g.18079A>G, NM_000767.4:c.415A>G, NP_000758.1:p.Lys139Glu, XM_005258569.1:c.415A>G, XM_005258569.3:c.415A>G, XM_005258570.1:c.415A>G, XM_005258571.1:c.295A>G, XM_006723050.2:c.415A>G, XM_011526546.1:c.415A>G, XM_011526547.1:c.415A>G, XM_011526548.1:c.415A>G, XM_011526549.1:c.-145A>G, XM_011526550.1:c.295A>G, XP_005258626.1:p.Lys139Glu, XP_005258627.1:p.Lys139Glu, XP_005258628.1:p.Lys99Glu, XP_006723113.1:p.Lys139Glu, XP_011524848.1:p.Lys139Glu, XP_011524849.1:p.Lys139Glu, XP_011524850.1:p.Lys139Glu, XP_011524852.1:p.Lys99Glu, rs56006122
A > G
SNP
K139E
No VIP available No Clinical Annotations available VA
rs12894467 NC_000014.8:g.101507727C>T, NC_000014.9:g.101041390C>T, NR_030582.1:n.28C>T, NR_031575.1:n.-1587C>T, rs60410947
C > T
SNP
No VIP available No Clinical Annotations available VA
rs13058338 NC_000022.10:g.37632770T>A, NC_000022.11:g.37236730T>A, NG_007288.1:g.12536A>T, NM_002872.3:c.108-3812A>T, NM_002872.4:c.108-3812A>T, XM_006724286.2:c.108-3812A>T, rs52805510
T > A
T > G
SNP
No VIP available No Clinical Annotations available VA
rs13059232 NC_000003.11:g.119521055T>C, NC_000003.12:g.119802208T>C, NG_011856.1:g.26725T>C, NM_003889.3:c.-22-5021T>C, NM_022002.2:c.96-5021T>C, NM_033013.2:c.-22-5021T>C, XM_005247866.1:c.-187-5021T>C, rs61609472
T > C
SNP
No VIP available No Clinical Annotations available VA
rs13181 NC_000019.10:g.45351661T>G, NC_000019.9:g.45854919T>G, NG_007067.2:g.23927A>C, NM_000400.3:c.2251A>C, NM_177417.2:c.*304T>G, NP_000391.1:p.Lys751Gln, XM_005258536.1:c.*128T>G, XM_005258536.3:c.*128T>G, XM_005258537.1:c.*128T>G, XM_005258538.1:c.*304T>G, XM_005258539.1:c.*304T>G, XM_005258639.1:c.2179A>C, XM_005258640.1:c.2017A>C, XM_005258641.1:c.1513A>C, XM_011526611.1:c.2173A>C, XP_005258696.1:p.Lys727Gln, XP_005258697.1:p.Lys673Gln, XP_005258698.1:p.Lys505Gln, XP_011524913.1:p.Lys725Gln, rs1052559, rs17285142, rs17355147, rs17359310, rs3170171, rs3859422, rs60606175
T > G
SNP
K751Q
No VIP available No Clinical Annotations available VA
rs1374749 NC_000002.11:g.46596433G>A, NC_000002.12:g.46369294G>A, NG_016000.1:g.76893G>A, NM_001430.4:c.780-533G>A, XM_011532698.1:c.819-533G>A, rs58613482
G > A
SNP
No VIP available CA VA
rs141059755 NC_000008.10:g.66107605A>C, NC_000008.10:g.66107605A>G, NC_000008.11:g.65195370A>C, NC_000008.11:g.65195370A>G
A > C
A > G
SNP
No VIP available CA VA
rs1570360 NC_000006.11:g.43737830A>G, NC_000006.12:g.43770093A>G, NG_008732.1:g.4878A>G, NM_001025366.2:c.-614A>G, NM_001025367.2:c.-614A>G, NM_001025368.2:c.-614A>G, NM_001025369.2:c.-614A>G, NM_001025370.2:c.-614A>G, NM_001033756.2:c.-614A>G, NM_001171622.1:c.-614A>G, NM_001171623.1:c.-1154A>G, NM_001171624.1:c.-1154A>G, NM_001171625.1:c.-1154A>G, NM_001171626.1:c.-1154A>G, NM_001171627.1:c.-1154A>G, NM_001171628.1:c.-1154A>G, NM_001171629.1:c.-1154A>G, NM_001171630.1:c.-1154A>G, NM_001204384.1:c.-1154A>G, NM_001204385.1:c.-614A>G, NM_001287044.1:c.-2027A>G, NM_001317010.1:c.-1154A>G, NM_003376.5:c.-614A>G, XM_005249363.1:c.-2027A>G, rs36208386, rs58036053
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1629140 NC_000014.8:g.34413826A>G, NC_000014.9:g.33944620A>G, NM_001308103.1:c.75+6058T>C, NM_022073.3:c.357+5776T>C, XM_006720015.2:c.75+6058T>C, rs17506218, rs60386310
A > G
SNP
No VIP available No Clinical Annotations available VA
rs168351 NC_000009.11:g.75517311A>G, NC_000009.12:g.72902395A>G, NG_012249.1:g.55659T>C, NM_000689.4:c.1434-1115T>C, XM_005251800.1:c.1434-1115T>C, XM_005251801.1:c.1374-1115T>C, rs2183402, rs635555
A > G
SNP
rs1695 NC_000011.10:g.67585218A>G, NC_000011.9:g.67352689A>G, NG_012075.1:g.6624A>G, NM_000852.3:c.313A>G, NP_000843.1:p.Ile105Val, XM_005273958.1:c.313A>G, XP_005274015.1:p.Ile105Val, rs1138257, rs11553891, rs17353321, rs17856342, rs2230827, rs4609, rs56971933, rs947894
A > G
SNP
I105V
No VIP available No Clinical Annotations available VA
rs16967126 NC_000016.10:g.16034561T>C, NC_000016.9:g.16128418T>C, NG_028268.1:g.89985T>C, NM_004996.3:c.677+1391T>C, NT_187607.1:g.1692461T>C, XM_005255326.1:c.677+1391T>C, XM_005255327.1:c.551+1391T>C, XM_005255328.1:c.539+1391T>C, XM_005255329.1:c.677+1391T>C, XM_011522497.1:c.653+1391T>C, XM_011522498.1:c.731+1391T>C, rs60727008
T > C
SNP
No VIP available CA VA
rs17021408 NC_000001.10:g.213943238T>C, NC_000001.11:g.213769895T>C, XR_922586.1:n.137-24489T>C, XR_922587.1:n.136+38337T>C
T > C
SNP
No VIP available No Clinical Annotations available VA
rs17222723 NC_000010.10:g.101595996T>A, NC_000010.11:g.99836239T>A, NG_011798.1:g.58534T>A, NM_000392.4:c.3563T>A, NP_000383.1:p.Val1188Glu, XM_005269536.1:c.3284T>A, XM_006717630.2:c.2867T>A, XP_005269593.1:p.Val1095Glu, XP_006717693.1:p.Val956Glu, XR_945604.1:n.3752T>A, XR_945605.1:n.3754T>A, rs52837755, rs59106280
T > A
SNP
V1188E
No VIP available No Clinical Annotations available VA
rs17655 NC_000013.10:g.103528002G>C, NC_000013.11:g.102875652G>C, NG_007146.1:g.34829G>C, NM_000123.3:c.3310G>C, NM_001204425.1:c.4672G>C, NP_000114.2:p.Asp1104His, NP_001191354.1:p.Asp1558His, rs16960665, rs3188002, rs3825521, rs52825398
G > C
SNP
D1104H
No VIP available CA VA
rs1799735 unknown
No VIP available No Clinical Annotations available VA
rs1799782 NC_000019.10:g.43553422G>A, NC_000019.9:g.44057574G>A, NG_033799.1:g.27157C>T, NM_006297.2:c.580C>T, NP_006288.2:p.Arg194Trp, rs11553655, rs2229674, rs3213359, rs3826914, rs386545546
G > A
SNP
R194W
No VIP available No Clinical Annotations available VA
rs1799793 NC_000019.10:g.45364001C>T, NC_000019.9:g.45867259C>T, NG_007067.2:g.11587G>A, NM_000400.3:c.934G>A, NM_001130867.1:c.862G>A, NP_000391.1:p.Asp312Asn, NP_001124339.1:p.Asp288Asn, XM_005258639.1:c.862G>A, XM_005258640.1:c.700G>A, XM_005258641.1:c.196G>A, XM_005258642.1:c.934G>A, XM_011526611.1:c.856G>A, XP_005258696.1:p.Asp288Asn, XP_005258697.1:p.Asp234Asn, XP_005258698.1:p.Asp66Asn, XP_005258699.1:p.Asp312Asn, XP_011524913.1:p.Asp286Asn, XR_935763.1:n.981G>A, rs3916814, rs58989209
C > T
SNP
D312N
No VIP available CA VA
rs1799983 NC_000007.13:g.150696111T>G, NC_000007.14:g.150999023T>G, NG_011992.1:g.12965T>G, NM_000603.4:c.894T>G, NM_001160109.1:c.894T>G, NM_001160110.1:c.894T>G, NM_001160111.1:c.894T>G, NP_000594.2:p.Asp298Glu, NP_001153581.1:p.Asp298Glu, NP_001153582.1:p.Asp298Glu, NP_001153583.1:p.Asp298Glu, XM_006716002.2:c.894T>G, XP_006716065.1:p.Asp298Glu, rs11266811, rs13238975, rs13305983, rs13308813, rs17173672, rs3730304, rs57135373
T > G
SNP
D298E
No VIP available No Clinical Annotations available VA
rs1800566 NC_000016.10:g.69711242G>A, NC_000016.9:g.69745145G>A, NG_011504.1:g.20389C>T, NM_000903.2:c.559C>T, NM_001025433.1:c.457C>T, NM_001025434.1:c.445C>T, NM_001286137.1:c.343C>T, NP_000894.1:p.Pro187Ser, NP_001020604.1:p.Pro153Ser, NP_001020605.1:p.Pro149Ser, NP_001273066.1:p.Pro115Ser, XM_005255830.1:c.343C>T, XP_005255887.1:p.Pro115Ser, rs4134727, rs4149351, rs57135274
G > A
SNP
P187S
No VIP available No Clinical Annotations available VA
rs1801131 NC_000001.10:g.11854476T>G, NC_000001.11:g.11794419T>G, NG_013351.1:g.16685A>C, NM_005957.4:c.1286A>C, NP_005948.3:p.Glu429Ala, XM_005263458.1:c.1409A>C, XM_005263458.2:c.1409A>C, XM_005263459.1:c.1355A>C, XM_005263460.1:c.1286A>C, XM_005263460.3:c.1286A>C, XM_005263461.1:c.1286A>C, XM_005263461.3:c.1286A>C, XM_005263462.1:c.1286A>C, XM_005263462.3:c.1286A>C, XM_005263463.1:c.1040A>C, XM_005263463.2:c.1040A>C, XM_011541495.1:c.1406A>C, XM_011541496.1:c.1409A>C, XP_005263515.1:p.Glu470Ala, XP_005263516.1:p.Glu452Ala, XP_005263517.1:p.Glu429Ala, XP_005263518.1:p.Glu429Ala, XP_005263519.1:p.Glu429Ala, XP_005263520.1:p.Glu347Ala, XP_011539797.1:p.Glu469Ala, XP_011539798.1:p.Glu470Ala, rs17367365, rs17857426, rs4134712
T > G
SNP
E429A
No VIP available CA VA
rs1801133 NC_000001.10:g.11856378G>A, NC_000001.11:g.11796321G>A, NG_013351.1:g.14783C>T, NM_005957.4:c.665C>T, NP_005948.3:p.Ala222Val, XM_005263458.1:c.788C>T, XM_005263458.2:c.788C>T, XM_005263459.1:c.734C>T, XM_005263460.1:c.665C>T, XM_005263460.3:c.665C>T, XM_005263461.1:c.665C>T, XM_005263461.3:c.665C>T, XM_005263462.1:c.665C>T, XM_005263462.3:c.665C>T, XM_005263463.1:c.419C>T, XM_005263463.2:c.419C>T, XM_011541495.1:c.785C>T, XM_011541496.1:c.788C>T, XP_005263515.1:p.Ala263Val, XP_005263516.1:p.Ala245Val, XP_005263517.1:p.Ala222Val, XP_005263518.1:p.Ala222Val, XP_005263519.1:p.Ala222Val, XP_005263520.1:p.Ala140Val, XP_011539797.1:p.Ala262Val, XP_011539798.1:p.Ala263Val, rs386545618, rs4134713, rs59514310
G > A
SNP
A222V
No VIP available CA VA
rs1801157
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1801274 NC_000001.10:g.161479745A>G, NC_000001.11:g.161509955A>G, NG_012066.1:g.9541A>G, NM_001136219.1:c.500A>G, NM_021642.3:c.497A>G, NP_001129691.1:p.His167Arg, NP_067674.2:p.His166Arg, XM_005244960.1:c.500A>G, XM_011509287.1:c.500A>G, XM_011509288.1:c.497A>G, XM_011509289.1:c.500A>G, XM_011509290.1:c.500A>G, XM_011509291.1:c.500A>G, XP_005245017.1:p.His167Arg, XP_011507589.1:p.His167Arg, XP_011507590.1:p.His166Arg, XP_011507591.1:p.His167Arg, XP_011507592.1:p.His167Arg, XP_011507593.1:p.His167Arg, rs16830404, rs17851761, rs386545630, rs52796393, rs58440466
A > G
SNP
H167R
No VIP available CA VA
rs1801280 NC_000008.10:g.18257854T>C, NC_000008.11:g.18400344T>C, NG_012246.1:g.14100T>C, NM_000015.2:c.341T>C, NP_000006.2:p.Ile114Thr, XM_011544358.1:c.341T>C, XP_011542660.1:p.Ile114Thr, rs4134724, rs56935242
T > C
SNP
I114T
No VIP available CA VA
rs1805087 NC_000001.10:g.237048500A>G, NC_000001.11:g.236885200A>G, NG_008959.1:g.94920A>G, NM_000254.2:c.2756A>G, NM_001291939.1:c.2603A>G, NM_001291940.1:c.1535A>G, NP_000245.2:p.Asp919Gly, NP_001278868.1:p.Asp868Gly, NP_001278869.1:p.Asp512Gly, XM_005273140.1:c.2924A>G, XM_005273141.1:c.2753A>G, XM_005273141.3:c.2753A>G, XM_005273142.1:c.2666A>G, XM_005273143.1:c.2603A>G, XM_005273144.1:c.2318A>G, XM_005273145.1:c.1118A>G, XM_006711769.2:c.2756A>G, XM_006711770.1:c.1820A>G, XM_011544193.1:c.2567A>G, XM_011544194.1:c.2924A>G, XP_005273197.1:p.Asp975Gly, XP_005273198.1:p.Asp918Gly, XP_005273199.1:p.Asp889Gly, XP_005273200.1:p.Asp868Gly, XP_005273201.1:p.Asp773Gly, XP_005273202.1:p.Asp373Gly, XP_006711832.1:p.Asp919Gly, XP_006711833.1:p.Asp607Gly, XP_011542495.1:p.Asp856Gly, XP_011542496.1:p.Asp975Gly, rs17658739, rs56618494, rs61036243
A > G
SNP
D919G
No VIP available No Clinical Annotations available VA
rs1883112 NC_000022.10:g.37256846G>A, NC_000022.11:g.36860804G>A, NG_023400.1:g.4817G>A, NM_000631.4:c.-368G>A, NM_013416.3:c.-368G>A, NT_187631.1:g.81598G>A, XM_011530198.1:c.-1851G>A, XM_011530199.1:c.-915G>A, rs13055287, rs34673077, rs61381844
G > A
SNP
No VIP available CA VA
rs1891059 NC_000001.10:g.213946009G>A, NC_000001.11:g.213772666G>A, XR_922586.1:n.137-21718G>A, XR_922587.1:n.136+41108G>A
G > A
SNP
No VIP available No Clinical Annotations available VA
rs197388 NC_000001.10:g.112297482A>T, NC_000001.11:g.111754860A>T, NM_007204.4:c.-1065A>T, NM_198926.2:c.12+841T>A, NR_125963.1:n.222+428T>A, XR_246395.1:n.249+428T>A, XR_246396.1:n.-1300T>A, rs59798432
A > T
SNP
No VIP available CA VA
rs2010963 NC_000006.11:g.43738350C>G, NC_000006.12:g.43770613C>G, NG_008732.1:g.5398C>G, NM_001025366.2:c.-94C>G, NM_001025367.2:c.-94C>G, NM_001025368.2:c.-94C>G, NM_001025369.2:c.-94C>G, NM_001025370.2:c.-94C>G, NM_001033756.2:c.-94C>G, NM_001171622.1:c.-94C>G, NM_001171623.1:c.-634C>G, NM_001171624.1:c.-634C>G, NM_001171625.1:c.-634C>G, NM_001171626.1:c.-634C>G, NM_001171627.1:c.-634C>G, NM_001171628.1:c.-634C>G, NM_001171629.1:c.-634C>G, NM_001171630.1:c.-634C>G, NM_001204384.1:c.-634C>G, NM_001204385.1:c.-94C>G, NM_001287044.1:c.-1507C>G, NM_001317010.1:c.-634C>G, NM_003376.5:c.-94C>G, XM_005249363.1:c.-1507C>G
C > G
SNP
No VIP available No Clinical Annotations available VA
rs2031920 NC_000010.10:g.135339845C>T, NC_000010.11:g.133526341C>T, NG_008383.1:g.3979C>T, NM_000773.3:c.-1055C>T, XM_005252665.1:c.-512C>T, rs3813868
C > T
SNP
No VIP available CA VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available CA VA
rs2070676 NC_000010.10:g.135351137G>C, NC_000010.11:g.133537633G>C, NG_008383.1:g.15271G>C, NM_000773.3:c.1156-118G>C, XM_005252665.1:c.1216-118G>C, rs17012756, rs56527359, rs59960595, rs60668193
G > C
SNP
No VIP available CA VA
rs2070744 NC_000007.13:g.150690079C=, NC_000007.13:g.150690079C>T, NC_000007.14:g.150992991C=, NC_000007.14:g.150992991C>T, NG_011992.1:g.6933C=, NG_011992.1:g.6933C>T, NM_000603.4:c.-51-762C=, NM_000603.4:c.-51-762C>T, NM_001160109.1:c.-813C=, NM_001160109.1:c.-813C>T, NM_001160110.1:c.-813C=, NM_001160110.1:c.-813C>T, NM_001160111.1:c.-813C=, NM_001160111.1:c.-813C>T, XM_006716002.2:c.-813C=, XM_006716002.2:c.-813C>T, rs10333298, rs34629525, rs61324345
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2114358 NC_000008.10:g.129021179G>A, NC_000008.11:g.128008933G>A, NR_003367.3:n.1212+19642G>A, NR_031611.1:n.36G>A, rs13269734, rs61088727
G > C
G > T
SNP
No VIP available No Clinical Annotations available VA
rs2228100 NC_000017.10:g.19642952G>C, NC_000017.11:g.19739639G>C, NG_012251.1:g.13795C>G, NM_000691.4:c.985C>G, NM_001135167.1:c.985C>G, NM_001135168.1:c.985C>G, NP_000682.3:p.Pro329Ala, NP_001128639.1:p.Pro329Ala, NP_001128640.1:p.Pro329Ala, XM_005256522.1:c.1336C>G, XM_005256523.1:c.1336C>G, XM_005256523.2:c.1336C>G, XM_005256524.1:c.1336C>G, XM_005256524.3:c.1336C>G, XM_005256525.1:c.1336C>G, XM_005256526.1:c.766C>G, XM_011523730.1:c.766C>G, XM_011523731.1:c.766C>G, XP_005256579.1:p.Pro446Ala, XP_005256580.1:p.Pro446Ala, XP_005256581.1:p.Pro446Ala, XP_005256582.1:p.Pro446Ala, XP_005256583.1:p.Pro256Ala, XP_011522032.1:p.Pro256Ala, XP_011522033.1:p.Pro256Ala, rs3744696, rs56956419
G > C
SNP
P329A
No VIP available CA VA
rs2229109 NC_000007.13:g.87179809C>T, NC_000007.14:g.87550493C>T, NG_011513.1:g.167756G>A, NM_000927.4:c.1199G>A, NP_000918.2:p.Ser400Asn, rs17276921, rs2235031, rs386561706, rs59635509
C > T
SNP
S400N
No VIP available No Clinical Annotations available VA
rs2230054 NC_000002.11:g.219000310C>T, NC_000002.12:g.218135587C>T, NM_001168298.1:c.786C>T, NM_001557.3:c.786C>T, NP_001161770.1:p.Leu262=, NP_001548.1:p.Leu262=, XM_005246529.1:c.786C>T, XM_005246530.1:c.786C>T, XM_005246530.2:c.786C>T, XM_005246531.1:c.786C>T, XP_005246586.1:p.Leu262=, XP_005246587.1:p.Leu262=, XP_005246588.1:p.Leu262=, rs17844700, rs2234672, rs3883989, rs57849916
C > T
SNP
L262L
No VIP available CA VA
rs2279343 NC_000019.10:g.41009358A>G, NC_000019.9:g.41515263A>G, NG_007929.1:g.23060A>G, NM_000767.4:c.785A>G, NP_000758.1:p.Lys262Arg, XM_005258569.1:c.785A>G, XM_005258569.3:c.785A>G, XM_005258570.1:c.785A>G, XM_005258571.1:c.365-2940A>G, XM_006723050.2:c.785A>G, XM_011526546.1:c.785A>G, XM_011526547.1:c.785A>G, XM_011526548.1:c.485-2940A>G, XM_011526549.1:c.194A>G, XM_011526550.1:c.365-2940A>G, XP_005258626.1:p.Lys262Arg, XP_005258627.1:p.Lys262Arg, XP_006723113.1:p.Lys262Arg, XP_011524848.1:p.Lys262Arg, XP_011524849.1:p.Lys262Arg, XP_011524851.1:p.Lys65Arg
A > G
SNP
K262R
No VIP available No Clinical Annotations available VA
rs2287584 NC_000005.10:g.31422900T>C, NC_000005.9:g.31423007T>C, NM_001100412.1:c.3195A>G, NM_013235.4:c.3306A>G, NP_001093882.1:p.Pro1065=, NP_037367.3:p.Pro1102=, XM_005248291.1:c.3306A>G, XM_005248291.2:c.3306A>G, XM_005248292.1:c.3282A>G, XM_005248292.2:c.3282A>G, XM_005248293.1:c.3213A>G, XM_005248293.2:c.3213A>G, XM_005248294.1:c.3102A>G, XM_005248294.2:c.3102A>G, XM_011514033.1:c.3306A>G, XP_005248348.1:p.Pro1102=, XP_005248349.1:p.Pro1094=, XP_005248350.1:p.Pro1071=, XP_005248351.1:p.Pro1034=, XP_011512335.1:p.Pro1102=, rs57044049
T > C
SNP
P1065P
No VIP available No Clinical Annotations available VA
rs2289030 NC_000012.11:g.95228286G>C, NC_000012.12:g.94834510G>C, NR_030171.1:n.113G>C, NR_036685.1:n.57G>C, rs59816854
G > C
SNP
No VIP available No Clinical Annotations available VA
rs2368393 NC_000010.10:g.29833998A>G, NC_000010.11:g.29545069A>G, NG_033998.1:g.195733T>C, NM_003174.3:c.827+5528T>C, NM_021738.2:c.827+5528T>C, NR_030335.1:n.29T>C, XM_005252564.1:c.1061+5528T>C, XM_005252565.1:c.1061+5528T>C, XM_005252566.1:c.1061+5528T>C, XM_005252567.1:c.1061+5528T>C, XM_005252568.1:c.1061+5528T>C, XM_005252569.1:c.1061+5528T>C, XM_005252570.1:c.827+5528T>C, XM_005252570.2:c.827+5528T>C, XM_005252571.1:c.827+5528T>C, XM_005252571.2:c.827+5528T>C, XM_005252572.1:c.827+5528T>C, XM_005252573.1:c.827+5528T>C, XM_005252573.2:c.827+5528T>C, XM_011519630.1:c.827+5528T>C, XM_011519631.1:c.827+5528T>C, XM_011519632.1:c.827+5528T>C, XM_011519633.1:c.827+5528T>C, XM_011519634.1:c.827+5528T>C, XM_011519635.1:c.827+5528T>C, XM_011519636.1:c.827+5528T>C, XM_011519637.1:c.827+5528T>C, XM_011519638.1:c.827+5528T>C, XM_011519639.1:c.827+5528T>C, XM_011519640.1:c.827+5528T>C
A > G
SNP
No VIP available No Clinical Annotations available VA
rs246221 NC_000016.10:g.16044465T=, NC_000016.10:g.16044465T>C, NC_000016.9:g.16138322T>C, NG_028268.1:g.99889T=, NG_028268.1:g.99889T>C, NM_004996.3:c.825T=, NM_004996.3:c.825T>C, NP_004987.2:p.Val275=, NT_187607.1:g.1702362C=, NT_187607.1:g.1702362C>T, XM_005255326.1:c.825T>C, XM_005255327.1:c.699T>C, XM_005255328.1:c.687T>C, XM_005255329.1:c.825T>C, XM_011522497.1:c.801T=, XM_011522497.1:c.801T>C, XM_011522498.1:c.879T=, XM_011522498.1:c.879T>C, XP_005255383.1:p.Val275=, XP_005255384.1:p.Val233=, XP_005255385.1:p.Val229=, XP_005255386.1:p.Val275=, XP_011520799.1:p.Val267=, XP_011520800.1:p.Val293=, rs1173290, rs17205745, rs2230670, rs248393, rs3816960, rs525646, rs61565643
T > C
SNP
V275V
No VIP available CA VA
rs25487 NC_000019.10:g.43551574T>C, NC_000019.9:g.44055726T>C, NG_033799.1:g.29005A>G, NM_006297.2:c.1196A>G, NP_006288.2:p.Gln399Arg, rs11553658, rs17435395, rs3817410, rs386493716, rs57378728
T > C
SNP
Q399R
No VIP available No Clinical Annotations available VA
rs25489 NC_000019.10:g.43552260C>T, NC_000019.9:g.44056412C>T, NG_033799.1:g.28319G>A, NM_006297.2:c.839G>A, NP_006288.2:p.Arg280His, rs17435388, rs2229675, rs2307183
C > T
SNP
R280H
No VIP available No Clinical Annotations available VA
rs2682818 NC_000012.11:g.81329536A>C, NC_000012.12:g.80935757A>C, NM_004664.2:c.82+1884T>G, NR_030349.1:n.77T>G, XM_005269212.1:c.82+1884T>G, XM_011538928.1:c.82+1884T>G, XM_011539062.1:c.-779A>C
A > G
A > T
SNP
No VIP available CA VA
rs2740574 NC_000007.13:g.99382096C>T, NC_000007.14:g.99784473C>T, NG_008421.1:g.4713G>A, NM_001202855.2:c.-392G>A, NM_017460.5:c.-392G>A, XM_011515841.1:c.-392G>A, XM_011515842.1:c.-392G>A, rs3176920, rs36231114, rs59393892
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2889517 NC_000016.10:g.16088099T>C, NC_000016.9:g.16181956T>C, NG_028268.1:g.143523T>C, NM_004996.3:c.2460+1108T>C, NT_187607.1:g.1745955T>C, XM_005255326.1:c.2460+1108T>C, XM_005255327.1:c.2334+1108T>C, XM_005255328.1:c.2322+1108T>C, XM_005255329.1:c.2283+1108T>C, XM_011522497.1:c.2436+1108T>C, XM_011522498.1:c.2367+1108T>C, rs58126671
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2910164 NC_000005.10:g.160485411C>G, NC_000005.9:g.159912418C>G, NR_029701.1:n.60C>G, NR_132748.1:n.303C>G, rs56537094, rs57852408, rs61270459
C > G
SNP
No VIP available No Clinical Annotations available VA
rs301927 NC_000003.11:g.97346618G>A, NC_000003.12:g.97627774G>A, NM_001080448.2:c.2575-10099G>A, NM_001278300.1:c.751-10099G>A, NM_173655.3:c.751-10099G>A, XM_006713592.2:c.2623-10099G>A, XR_924127.1:n.1030-10099G>A, rs1684641, rs61169431
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3025030 NC_000006.11:g.43750587G>C, NC_000006.12:g.43782850G>C, NG_008732.1:g.17635G>C, NM_001025366.2:c.1217+763G>C, NM_001025367.2:c.1148+763G>C, NM_001025368.2:c.1094+763G>C, NM_001025369.2:c.1059+798G>C, NM_001025370.2:c.963-1691G>C, NM_001033756.2:c.1094+763G>C, NM_001171622.1:c.933-1691G>C, NM_001171623.1:c.677+763G>C, NM_001171624.1:c.626+763G>C, NM_001171625.1:c.608+763G>C, NM_001171626.1:c.554+763G>C, NM_001171627.1:c.519+798G>C, NM_001171628.1:c.423-1691G>C, NM_001171629.1:c.554+763G>C, NM_001171630.1:c.393-1691G>C, NM_001204384.1:c.495-1691G>C, NM_001204385.1:c.1035-1691G>C, NM_001287044.1:c.470+763G>C, NM_001317010.1:c.554+763G>C, NM_003376.5:c.1166+763G>C, XM_005249363.1:c.470+763G>C, rs16896816, rs3799959, rs61356923
G > C
SNP
No VIP available No Clinical Annotations available VA
rs3025033 NC_000006.11:g.43751075A>G, NC_000006.12:g.43783338A>G, NG_008732.1:g.18123A>G, NM_001025366.2:c.1218-1203A>G, NM_001025367.2:c.1149-1203A>G, NM_001025368.2:c.1095-1203A>G, NM_001025369.2:c.1060-1203A>G, NM_001025370.2:c.963-1203A>G, NM_001033756.2:c.1094+1251A>G, NM_001171622.1:c.933-1203A>G, NM_001171623.1:c.678-1203A>G, NM_001171624.1:c.627-1203A>G, NM_001171625.1:c.609-1203A>G, NM_001171626.1:c.555-1203A>G, NM_001171627.1:c.520-1203A>G, NM_001171628.1:c.423-1203A>G, NM_001171629.1:c.554+1251A>G, NM_001171630.1:c.393-1203A>G, NM_001204384.1:c.495-1203A>G, NM_001204385.1:c.1035-1203A>G, NM_001287044.1:c.471-1203A>G, NM_001317010.1:c.555-1203A>G, NM_003376.5:c.1167-1203A>G, XM_005249363.1:c.471-1203A>G, rs3778502, rs59547322
A > G
SNP
No VIP available No Clinical Annotations available VA
rs3025039 NC_000006.11:g.43752536C>T, NC_000006.12:g.43784799C>T, NG_008732.1:g.19584C>T, NM_001025366.2:c.*237C>T, NM_001025367.2:c.*237C>T, NM_001025368.2:c.*237C>T, NM_001025369.2:c.*253C>T, NM_001025370.2:c.*237C>T, NM_001033756.2:c.*171C>T, NM_001171622.1:c.*237C>T, NM_001171623.1:c.*237C>T, NM_001171624.1:c.*237C>T, NM_001171625.1:c.*237C>T, NM_001171626.1:c.*237C>T, NM_001171627.1:c.*253C>T, NM_001171628.1:c.*237C>T, NM_001171629.1:c.*171C>T, NM_001171630.1:c.*237C>T, NM_001204384.1:c.*237C>T, NM_001204385.1:c.*237C>T, NM_001287044.1:c.*237C>T, NM_001317010.1:c.*171C>T, NM_003376.5:c.*237C>T, XM_005249363.1:c.*237C>T, rs11575898
C > T
SNP
No VIP available CA VA
rs3211371 NC_000019.10:g.41016810C>T, NC_000019.9:g.41522715C>T, NG_007929.1:g.30512C>T, NM_000767.4:c.1459C>T, NP_000758.1:p.Arg487Cys, XM_005258569.1:c.*48C>T, XM_005258569.3:c.*48C>T, XM_005258570.1:c.*214C>T, XM_005258571.1:c.859C>T, XM_006723050.2:c.*143C>T, XM_011526547.1:c.*214C>T, XM_011526548.1:c.979C>T, XM_011526549.1:c.868C>T, XM_011526550.1:c.859C>T, XP_005258628.1:p.Arg287Cys, XP_011524850.1:p.Arg327Cys, XP_011524851.1:p.Arg290Cys, XP_011524852.1:p.Arg287Cys, rs12721654, rs28399500, rs33995163, rs58951873
C > T
SNP
R487C
No VIP available No Clinical Annotations available VA
rs3212986 NC_000019.10:g.45409478C>A, NC_000019.9:g.45912736C>A, NG_015839.2:g.74351G>T, NM_001166049.1:c.*197G>T, NM_001297590.1:c.1516C>A, NM_001983.3:c.*197G>T, NM_012099.1:c.1510C>A, NP_001284519.1:p.Gln506Lys, NP_036231.1:p.Gln504Lys, XM_005258425.1:c.1516C>A, XM_005258638.1:c.*197G>T, XP_005258482.1:p.Gln506Lys, rs386580934, rs60333438
C > A
C > T
SNP
Q506K
No VIP available No Clinical Annotations available VA
rs3213619 NC_000007.13:g.87230193A>G, NC_000007.14:g.87600877A>G, NG_011513.1:g.117372T>C, NM_000927.4:c.-129T>C, rs17249446, rs60679736
A > G
SNP
No VIP available CA VA
rs3219484 NC_000001.10:g.45800156C>T, NC_000001.11:g.45334484C>T, NG_008189.1:g.10987G>A, NM_001048171.1:c.64G>A, NM_001048172.1:c.22G>A, NM_001048173.1:c.22G>A, NM_001048174.1:c.22G>A, NM_001128425.1:c.64G>A, NM_001293190.1:c.64G>A, NM_001293191.1:c.22G>A, NM_001293192.1:c.-191G>A, NM_001293195.1:c.22G>A, NM_001293196.1:c.-191G>A, NM_012222.2:c.64G>A, NP_001041636.1:p.Val22Met, NP_001041637.1:p.Val8Met, NP_001041638.1:p.Val8Met, NP_001041639.1:p.Val8Met, NP_001121897.1:p.Val22Met, NP_001280119.1:p.Val22Met, NP_001280120.1:p.Val8Met, NP_001280124.1:p.Val8Met, NP_036354.1:p.Val22Met, XM_005270880.1:c.64G>A, XM_005270881.1:c.22G>A, XM_005270882.1:c.22G>A, XM_005270883.1:c.-135G>A, XM_005270884.1:c.-191G>A, XM_005270885.1:c.-191G>A, XM_005270886.1:c.-52G>A, XM_011541497.1:c.40G>A, XM_011541498.1:c.22G>A, XM_011541499.1:c.22G>A, XM_011541500.1:c.22G>A, XM_011541501.1:c.22G>A, XM_011541502.1:c.22G>A, XM_011541503.1:c.64G>A, XM_011541504.1:c.22G>A, XM_011541505.1:c.-52G>A, XM_011541506.1:c.-52G>A, XM_011541507.1:c.-1167G>A, XM_011541508.1:c.-1194G>A, XP_005270937.1:p.Val22Met, XP_005270938.1:p.Val8Met, XP_005270939.1:p.Val8Met, XP_011539799.1:p.Val14Met, XP_011539800.1:p.Val8Met, XP_011539801.1:p.Val8Met, XP_011539802.1:p.Val8Met, XP_011539803.1:p.Val8Met, XP_011539804.1:p.Val8Met, XP_011539805.1:p.Val22Met, XP_011539806.1:p.Val8Met, XR_946658.1:n.111G>A, rs17784895, rs52809192, rs61197742
C > T
SNP
V22M
No VIP available No Clinical Annotations available VA
rs34115976 NC_000004.11:g.115577997C>G, NC_000004.12:g.114656841C>G, NM_001128174.1:c.823-7154C>G, NM_003360.3:c.823-7154C>G, NR_030303.1:n.83C>G, XM_006714302.2:c.823-7154C>G, XM_006714303.2:c.823-7154C>G, XM_011532232.1:c.823-7154C>G, XR_244645.1:n.1052-7154C>G
C > G
SNP
No VIP available No Clinical Annotations available VA
rs34324334 NC_000006.11:g.43535018C>T, NC_000006.12:g.43567281C>T, NM_020750.2:c.722G>A, NP_065801.1:p.Ser241Asn
C > T
SNP
S241N
No VIP available CA VA
rs351855 NC_000005.10:g.177093242G>A, NC_000005.9:g.176520243G>A, NG_012067.1:g.11323G>A, NM_001291980.1:c.1097+65G>A, NM_002011.4:c.1162G>A, NM_022963.3:c.1058-90G>A, NM_213647.2:c.1162G>A, NP_002002.3:p.Gly388Arg, NP_998812.1:p.Gly388Arg, XM_005265837.1:c.1258G>A, XM_005265838.1:c.1162G>A, XM_005265838.2:c.1162G>A, XM_005265839.1:c.1097+65G>A, XM_011534464.1:c.1255G>A, XM_011534465.1:c.844G>A, XP_005265894.1:p.Gly420Arg, XP_005265895.1:p.Gly388Arg, XP_011532766.1:p.Gly419Arg, XP_011532767.1:p.Gly282Arg, XR_941090.1:n.1207G>A, rs117475361, rs56695235
G > A
SNP
G388R
No VIP available No Clinical Annotations available VA
rs35596 NC_000016.10:g.16059083T=, NC_000016.10:g.16059083T>C, NC_000016.9:g.16152940T>C, NG_028268.1:g.114507T=, NG_028268.1:g.114507T>C, NM_004996.3:c.1677+2788C>T, NM_004996.3:c.1677+2788T>C, NT_187607.1:g.1716974C=, NT_187607.1:g.1716974C>T, XM_005255326.1:c.1677+2788T>C, XM_005255327.1:c.1551+2788T>C, XM_005255328.1:c.1539+2788T>C, XM_005255329.1:c.1677+2788T>C, XM_011522497.1:c.1653+2788C>T, XM_011522497.1:c.1653+2788T>C, XM_011522498.1:c.1731+2788C>T, XM_011522498.1:c.1731+2788T>C, rs426546, rs559627, rs60012681
T > C
SNP
No VIP available No Clinical Annotations available VA
rs3744741 NC_000017.10:g.649232C>T, NC_000017.11:g.745992C>T, NM_015721.2:c.2051G>A, NP_056536.2:p.Arg684Gln, XM_005256667.1:c.2063G>A, XM_005256667.3:c.2063G>A, XM_005256668.1:c.2063G>A, XM_005256668.3:c.2063G>A, XM_005256669.1:c.2018G>A, XM_005256670.1:c.2018G>A, XM_005256670.3:c.2018G>A, XM_011523910.1:c.2063G>A, XM_011523911.1:c.2063G>A, XM_011523912.1:c.2018G>A, XM_011523913.1:c.2018G>A, XP_005256724.1:p.Arg688Gln, XP_005256725.1:p.Arg688Gln, XP_005256726.1:p.Arg673Gln, XP_005256727.1:p.Arg673Gln, XP_011522212.1:p.Arg688Gln, XP_011522213.1:p.Arg688Gln, XP_011522214.1:p.Arg673Gln, XP_011522215.1:p.Arg673Gln, rs56482056, rs59343482
C > T
SNP
R684Q
No VIP available CA VA
rs3745274 NC_000019.10:g.41006936G>T, NC_000019.9:g.41512841G>T, NG_007929.1:g.20638G>T, NM_000767.4:c.516G>T, NP_000758.1:p.Gln172His, XM_005258569.1:c.516G>T, XM_005258569.3:c.516G>T, XM_005258570.1:c.516G>T, XM_005258571.1:c.364+2490G>T, XM_006723050.2:c.516G>T, XM_011526546.1:c.516G>T, XM_011526547.1:c.516G>T, XM_011526548.1:c.484+2490G>T, XM_011526549.1:c.-75-1G>T, XM_011526550.1:c.364+2490G>T, XP_005258626.1:p.Gln172His, XP_005258627.1:p.Gln172His, XP_006723113.1:p.Gln172His, XP_011524848.1:p.Gln172His, XP_011524849.1:p.Gln172His, rs56308434, rs57685583
G > T
SNP
Q172H
No VIP available No Clinical Annotations available VA
rs3764435 NC_000009.11:g.75516876A>C, NC_000009.12:g.72901960A>C, NG_012249.1:g.56094T>G, NM_000689.4:c.1434-680T>G, XM_005251800.1:c.1434-680T>G, XM_005251801.1:c.1374-680T>G
A > C
SNP
No VIP available No Clinical Annotations available VA
rs3768728 NC_000002.11:g.46590791T>C, NC_000002.12:g.46363652T>C, NG_016000.1:g.71251T>C, NM_001430.4:c.779+2562T>C, XM_011532698.1:c.818+2562T>C, rs60273833
T > C
SNP
No VIP available No Clinical Annotations available VA
rs3805500 NC_000005.10:g.31462870G>A, NC_000005.9:g.31462977G>A, NM_001100412.1:c.2463+1366C>T, NM_013235.4:c.2574+1366C>T, XM_005248291.1:c.2574+1366C>T, XM_005248291.2:c.2574+1366C>T, XM_005248292.1:c.2550+1366C>T, XM_005248292.2:c.2550+1366C>T, XM_005248293.1:c.2481+1366C>T, XM_005248293.2:c.2481+1366C>T, XM_005248294.1:c.2370+1366C>T, XM_005248294.2:c.2370+1366C>T, XM_011514033.1:c.2574+1366C>T, rs386586733
G > A
SNP
No VIP available CA VA
rs3824662 NC_000010.10:g.8104208C>A, NC_000010.11:g.8062245C>A, NG_015859.1:g.12542C>A, NM_001002295.1:c.779-1748C>A, NM_002051.2:c.779-1751C>A, XM_005252442.1:c.779-1748C>A, XM_005252442.2:c.779-1748C>A, XM_005252443.1:c.779-1748C>A, XM_005252443.3:c.779-1748C>A, rs11567915
C > A
SNP
No VIP available No Clinical Annotations available VA
rs3829306 NC_000012.11:g.21292280C>T, NC_000012.12:g.21139346C>T, NG_011745.1:g.13153C>T, NM_006446.4:c.-61-2168C>T, rs52794315, rs59551499
C > T
SNP
No VIP available CA VA
rs3957356 NC_000006.11:g.52668670T>C, NC_000006.12:g.52803872T>C, NM_001319059.1:c.-264A>G, NM_145740.4:c.-118A>G, XM_005249034.1:c.-118A>G, XM_005249034.2:c.-118A>G, rs59071523
T > C
SNP
No VIP available CA VA
rs3957357 NC_000006.11:g.52668687A>G, NC_000006.12:g.52803889A>G, NM_001319059.1:c.-281T>C, NM_145740.4:c.-135T>C, XM_005249034.1:c.-135T>C, XM_005249034.2:c.-135T>C, rs58145964
A > G
SNP
No VIP available No Clinical Annotations available VA
rs396991 NC_000001.10:g.161514542A>C, NC_000001.11:g.161544752A>C, NG_009066.1:g.10872T>G, NM_000569.6:c.634T>G, NM_001127592.1:c.631T>G, NM_001127593.1:c.526T>G, NM_001127595.1:c.526T>G, NM_001127596.1:c.523T>G, NP_000560.5:p.Phe212Val, NP_001121064.1:p.Phe211Val, NP_001121065.1:p.Phe176Val, NP_001121067.1:p.Phe176Val, NP_001121068.1:p.Phe175Val, XM_011509293.1:c.428-1553T>G, rs17857127, rs2229097, rs3171040, rs4151086, rs61228128
A > C
SNP
F212V
No VIP available No Clinical Annotations available VA
rs4073 NC_000004.11:g.74606024A>T, NC_000004.12:g.73740307A>T, NG_029889.1:g.4802A>T, NM_000584.3:c.-352A>T
A > T
SNP
No VIP available CA VA
rs4135385 NC_000003.11:g.41279440A>G, NC_000003.12:g.41237949A>G, NG_013302.1:g.43499A>G, NM_001098209.1:c.2077-67A>G, NM_001098210.1:c.2077-67A>G, NM_001904.3:c.2077-67A>G, XM_005264886.1:c.2077-67A>G, XM_005264886.2:c.2077-67A>G, XM_005264887.1:c.2077-67A>G, XM_005264888.1:c.2077-67A>G, XM_006712983.1:c.2056-67A>G, XM_006712984.1:c.2056-67A>G, XM_006712985.1:c.2076+1240A>G, rs58718635
A > G
SNP
No VIP available No Clinical Annotations available VA
rs4148350 NC_000016.10:g.16076620G>T, NC_000016.9:g.16170477G>T, NG_028268.1:g.132044G>T, NM_004996.3:c.1988+219G>T, NT_187607.1:g.1734472G>T, XM_005255326.1:c.1988+219G>T, XM_005255327.1:c.1862+219G>T, XM_005255328.1:c.1850+219G>T, XM_005255329.1:c.1988+219G>T, XM_011522497.1:c.1964+219G>T, XM_011522498.1:c.1895+219G>T, rs587779726, rs60127316
G > T
SNP
No VIP available No Clinical Annotations available VA
rs4148354 NC_000016.10:g.16080649G>A, NC_000016.9:g.16174506G>A, NG_028268.1:g.136073G>A, NM_004996.3:c.2115+1171G>A, NT_187607.1:g.1738501G>A, XM_005255326.1:c.2115+1171G>A, XM_005255327.1:c.1989+1171G>A, XM_005255328.1:c.1977+1171G>A, XM_005255329.1:c.2115+1171G>A, XM_011522497.1:c.2091+1171G>A, XM_011522498.1:c.2022+1171G>A, rs58159089
G > A
SNP
No VIP available CA VA
rs4148416 NC_000017.10:g.48753423C>T, NC_000017.11:g.50676062C>T, NM_003786.3:c.3039C>T, NP_003777.2:p.Gly1013=, XM_005257763.1:c.2847C>T, XM_005257763.2:c.2847C>T, XM_011525422.1:c.2952C>T, XM_011525423.1:c.3144C>T, XM_011525424.1:c.2364C>T, XM_011525425.1:c.2313C>T, XP_005257820.1:p.Gly949=, XP_011523724.1:p.Gly984=, XP_011523725.1:p.Gly1048=, XP_011523726.1:p.Gly788=, XP_011523727.1:p.Gly771=, XR_934586.1:n.3237C>T
C > T
SNP
G1013G
No VIP available CA VA
rs4148737 NC_000007.13:g.87171152T>C, NC_000007.14:g.87541836T>C, NG_011513.1:g.176413A>G, NM_000927.4:c.2212-372A>G, rs386591482, rs60838665
T > C
SNP
No VIP available CA VA
rs4149056 NC_000012.11:g.21331549T>C, NC_000012.12:g.21178615T>C, NG_011745.1:g.52422T>C, NM_006446.4:c.521T>C, NP_006437.3:p.Val174Ala, rs52816141, rs60037639
T > C
SNP
V174A
rs4244285 NC_000010.10:g.96541616G>A, NC_000010.11:g.94781859G>A, NG_008384.2:g.24154G>A, NM_000769.1:c.681G>A, NM_000769.2:c.681G>A, NP_000760.1:p.Pro227=, rs116940633, rs17879456, rs60361278
G > A
SNP
P227P
No VIP available No Clinical Annotations available VA
rs45445694 NC_000018.10:g.657646_657673CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NC_000018.9:g.657646_657673CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NG_028255.1:g.5043_5070CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], NM_001012716.2:c.*34+169_*34+196CGGGACGGAGGCAGGCCAAGTGGCGCGG[2][3][4][7][8][9], NM_001071.2:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], XM_005258137.1:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9], XM_005258138.1:c.-97_-70CCGCGCCACTTGGCCTGCCTCCGTCCCG[2][3][4][7][8][9]
CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3 > (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2
CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3 > (CCGCGCCACTTGGCCTGCCTCCGTCCCG)4
CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3 > (CCGCGCCACTTGGCCTGCCTCCGTCCCG)7
CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3 > (CCGCGCCACTTGGCCTGCCTCCGTCCCG)8
CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3 > (CCGCGCCACTTGGCCTGCCTCCGTCCCG)9
microsatellite
No VIP available CA VA
rs4646 NC_000015.10:g.51210647A>C, NC_000015.9:g.51502844A>C, NG_007982.1:g.132952T>G, NM_000103.3:c.*161T>G, NM_031226.2:c.*161T>G, XM_005254190.1:c.*161T>G, XM_005254191.1:c.*161T>G, XM_005254192.1:c.*161T>G, XR_932222.1:n.99-67336A>C, rs16964193, rs3191019, rs58335330
A > C
SNP
No VIP available CA VA
rs4673 NC_000016.10:g.88646828A>G, NC_000016.9:g.88713236A>G, NG_007291.1:g.9222T>C, NM_000101.2:c.214T>C, NM_000101.3:c.214T>C, NP_000092.2:p.Tyr72His, XM_011522905.1:c.214T>C, XP_011521207.1:p.Tyr72His, rs11266997, rs1130413, rs2228471, rs2242272, rs3189211, rs386594564, rs4782392, rs59455247
A > G
SNP
Y72H
No VIP available CA VA
rs4802101 NC_000019.10:g.40990556T>C, NC_000019.9:g.41496461T>C, NG_007929.1:g.4258T>C, NM_000767.4:c.-750T>C, XM_005258569.1:c.-750T>C, XM_005258569.3:c.-750T>C, XM_005258570.1:c.-750T>C, XM_006723050.2:c.-750T>C, XM_011526546.1:c.-750T>C, XM_011526547.1:c.-750T>C, XM_011526548.1:c.-750T>C, rs12721647, rs61382311
T > C
SNP
No VIP available No Clinical Annotations available VA
rs4803419 NC_000019.10:g.41006887C>T, NC_000019.9:g.41512792C>T, NG_007929.1:g.20589C>T, NM_000767.4:c.485-18C>T, XM_005258569.1:c.485-18C>T, XM_005258569.3:c.485-18C>T, XM_005258570.1:c.485-18C>T, XM_005258571.1:c.364+2441C>T, XM_006723050.2:c.485-18C>T, XM_011526546.1:c.485-18C>T, XM_011526547.1:c.485-18C>T, XM_011526548.1:c.484+2441C>T, XM_011526549.1:c.-75-50C>T, XM_011526550.1:c.364+2441C>T, rs60830962
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4867329 NC_000005.10:g.31435520A>C, NC_000005.9:g.31435627A>C, NM_001100412.1:c.2931+245T>G, NM_013235.4:c.3042+245T>G, XM_005248291.1:c.3042+245T>G, XM_005248291.2:c.3042+245T>G, XM_005248292.1:c.3018+245T>G, XM_005248292.2:c.3018+245T>G, XM_005248293.1:c.2949+245T>G, XM_005248293.2:c.2949+245T>G, XM_005248294.1:c.2838+245T>G, XM_005248294.2:c.2838+245T>G, XM_011514033.1:c.3042+245T>G, rs17485775
A > C
SNP
No VIP available CA VA
rs4880 NC_000006.11:g.160113872A>G, NC_000006.12:g.159692840A>G, NG_008729.1:g.5482T>C, NM_000636.2:c.47T>C, NM_001024465.1:c.47T>C, NM_001024466.1:c.47T>C, NP_000627.2:p.Val16Ala, NP_001019636.1:p.Val16Ala, NP_001019637.1:p.Val16Ala, rs1141717, rs11551083, rs116851270, rs17362379, rs17405198, rs17856520, rs1799725, rs3205539, rs386596107
A > G
SNP
V16A
No VIP available No Clinical Annotations available VA
rs4953344 NC_000002.11:g.46552458T>C, NC_000002.12:g.46325319T>C, NG_016000.1:g.32918T>C, NM_001430.4:c.27-21554T>C, XM_011532698.1:c.-493T>C, XR_940055.1:n.2355+10465A>G, rs17746007, rs56802594
T > C
SNP
rs4986893 NC_000010.10:g.96540410G>A, NC_000010.11:g.94780653G>A, NG_008384.2:g.22948G>A, NM_000769.2:c.636G>A, NP_000760.1:p.Trp212Ter, rs52827375, rs57081121
G > A
SNP
W212*
No VIP available No Clinical Annotations available VA
rs56103835 NC_000014.8:g.101522556T>C, NC_000014.9:g.101056219T>C, NR_036133.1:n.1T>C
T > A
T > C
SNP
No VIP available No Clinical Annotations available VA
rs595961 NC_000001.10:g.36367780A>G, NC_000001.11:g.35902179A>G, NM_001317122.1:c.1264-25A>G, NM_001317123.1:c.1039-25A>G, NM_012199.4:c.1264-25A>G, XM_005270746.1:c.1246-25A>G, XM_005270747.1:c.1039-25A>G, XM_011541236.1:c.1273-25A>G, XM_011541237.1:c.1048-25A>G, XM_011541238.1:c.1039-25A>G, XM_011541239.1:c.820-25A>G, rs59876085
A > G
SNP
No VIP available CA VA
rs6151031 NC_000009.11:g.75568383_75568384insCTGGTGAGGAGAGAACC, NC_000009.12:g.72953467_72953468insCTGGTGAGGAGAGAACC, NG_012249.1:g.4586_4587insGGTTCTCTCCTCACCAG, NM_000689.4:c.-468_-467insGGTTCTCTCCTCACCAG, XM_005251800.1:c.-14-454_-14-453insGGTTCTCTCCTCACCAG, rs142856037
- > CTGGTGAGGAGAGAACC
indel
No VIP available No Clinical Annotations available VA
rs63319 NC_000009.11:g.75524784G>T, NC_000009.12:g.72909868G>T, NG_012249.1:g.48186C>A, NM_000689.4:c.1201-109C>A, XM_005251800.1:c.1201-109C>A, XM_005251801.1:c.1141-109C>A, rs386602334, rs604561, rs726191
G > T
SNP
No VIP available CA VA
rs639174 NC_000005.10:g.31433540C>T, NC_000005.9:g.31433647C>T, NM_001100412.1:c.2932-1862G>A, NM_013235.4:c.3043-1862G>A, XM_005248291.1:c.3043-1862G>A, XM_005248291.2:c.3043-1862G>A, XM_005248292.1:c.3019-1862G>A, XM_005248292.2:c.3019-1862G>A, XM_005248293.1:c.2950-1862G>A, XM_005248293.2:c.2950-1862G>A, XM_005248294.1:c.2839-1862G>A, XM_005248294.2:c.2839-1862G>A, XM_011514033.1:c.3043-1862G>A, rs57933113
C > T
SNP
No VIP available CA VA
rs6413432 NC_000010.10:g.135348544T>A, NC_000010.11:g.133535040T>A, NG_008383.1:g.12678T>A, NM_000773.3:c.967+1143T>A, XM_005252665.1:c.1027+1143T>A
T > A
SNP
No VIP available No Clinical Annotations available VA
rs6473187 NC_000008.10:g.48483958G>A, NC_000008.11:g.47571396G>A, NM_001080394.3:c.1098-24415G>A, NM_001282916.1:c.888-24415G>A, NM_001282919.1:c.918-24415G>A, NR_104581.1:n.827-24415G>A, XM_005251189.1:c.1098-24415G>A, XM_005251189.2:c.1098-24415G>A, XM_005251190.1:c.918-24415G>A, XM_005251191.1:c.1098-24415G>A, XM_005251191.2:c.1098-24415G>A, XM_005251192.1:c.888-24415G>A, XM_005251193.1:c.1098-24415G>A, XM_005251193.2:c.1098-24415G>A, XM_005251194.1:c.627-24415G>A, XM_005251195.1:c.606-24415G>A, XM_005251195.3:c.606-24415G>A, XM_005251196.1:c.579-24415G>A, XM_005251197.1:c.576-24415G>A, XM_005251197.3:c.576-24415G>A, XM_005251198.1:c.348-24415G>A, XM_005251198.3:c.348-24415G>A, XM_005251199.1:c.165-24415G>A, XM_005251199.3:c.165-24415G>A, XM_005251200.1:c.30-24415G>A, XM_006716443.2:c.918-24415G>A, XM_006716444.2:c.348-24415G>A, XM_006716445.2:c.12-24415G>A, XM_011517497.1:c.1098-24415G>A, XM_011517498.1:c.1098-24415G>A, XM_011517499.1:c.1098-24415G>A, XM_011517500.1:c.978-24415G>A, XM_011517501.1:c.663-24415G>A, XM_011517502.1:c.627-24415G>A, XM_011517503.1:c.600-24415G>A, XM_011517504.1:c.45-24415G>A, XM_011517505.1:c.30-24415G>A, XM_011517506.1:c.-151-24415G>A, XR_242455.1:n.1121-24415G>A, rs59757374
G > A
SNP
No VIP available No Clinical Annotations available VA
rs6497759 NC_000016.10:g.24790416G>A, NC_000016.9:g.24801737G>A, NM_014494.2:c.1774G>A, NP_055309.2:p.Ala592Thr, XM_005255253.1:c.1678G>A, XM_005255254.1:c.1774G>A, XM_005255254.2:c.1774G>A, XM_005255255.1:c.1678G>A, XM_005255256.1:c.1678G>A, XM_005255257.1:c.1015G>A, XM_005255257.3:c.1015G>A, XM_006721039.2:c.1348G>A, XM_011545791.1:c.1774G>A, XM_011545792.1:c.1774G>A, XM_011545793.1:c.1774G>A, XM_011545794.1:c.1774G>A, XM_011545795.1:c.1774G>A, XM_011545796.1:c.1774G>A, XP_005255310.1:p.Ala560Thr, XP_005255311.1:p.Ala592Thr, XP_005255312.1:p.Ala560Thr, XP_005255313.1:p.Ala560Thr, XP_005255314.1:p.Ala339Thr, XP_006721102.1:p.Ala450Thr, XP_011544093.1:p.Ala592Thr, XP_011544094.1:p.Ala592Thr, XP_011544095.1:p.Ala592Thr, XP_011544096.1:p.Ala592Thr, XP_011544097.1:p.Ala592Thr, XP_011544098.1:p.Ala592Thr, rs52832662, rs59562937
G > A
SNP
A592T
No VIP available No Clinical Annotations available VA
rs6505162 NC_000017.10:g.28444183A>C, NC_000017.11:g.30117165A>C, NM_001261467.1:c.-49+302A>C, NM_032141.3:c.20+302A>C, NR_029945.1:n.87A>C, NR_036149.1:n.-5T>G, XM_005258042.1:c.20+302A>C, XM_011525345.1:c.21-137A>C, XR_934651.1:n.682+227T>G, rs56453081, rs61093106
A > C
A > T
SNP
No VIP available CA VA
rs6907567 NC_000006.11:g.110777962A>G, NC_000006.12:g.110456759A>G, NM_033125.3:c.312T>C, NP_149116.2:p.Asn104=, XM_005267183.1:c.216T>C, XM_005267184.1:c.23+141T>C, XM_005267184.2:c.23+141T>C, XM_005267185.1:c.-151T>C, XM_011536204.1:c.183T>C, XM_011536205.1:c.312T>C, XM_011536206.1:c.171+141T>C, XM_011536207.1:c.179+141T>C, XM_011536208.1:c.143+141T>C, XM_011536209.1:c.128+141T>C, XM_011536210.1:c.312T>C, XM_011536211.1:c.171+141T>C, XM_011536212.1:c.-261T>C, XP_005267240.1:p.Asn72=, XP_011534506.1:p.Asn61=, XP_011534507.1:p.Asn104=, XP_011534512.1:p.Asn104=
A > G
SNP
N104N
No VIP available CA VA
rs698 NC_000004.11:g.100260789T>C, NC_000004.12:g.99339632T>C, NG_011718.1:g.18129A>G, NM_000669.4:c.1048A>G, NP_000660.1:p.Ile350Val, NR_133005.1:n.1374A>G, XM_011531588.1:c.946A>G, XM_011531589.1:c.928A>G, XP_011529890.1:p.Ile316Val, XP_011529891.1:p.Ile310Val, rs1042758, rs117472071, rs1693473, rs17399447, rs17855753, rs3182222, rs4134508, rs56906178
T > -
T > C
SNP
I350V
No VIP available No Clinical Annotations available VA
rs699947 NC_000006.11:g.43736389A>C, NC_000006.12:g.43768652A>C, NG_008732.1:g.3437A>C, NM_001025366.2:c.-2055A>C, NM_001025367.2:c.-2055A>C, NM_001025368.2:c.-2055A>C, NM_001025369.2:c.-2055A>C, NM_001025370.2:c.-2055A>C, NM_001033756.2:c.-2055A>C, NM_001171622.1:c.-2055A>C, NM_001171623.1:c.-2595A>C, NM_001171624.1:c.-2595A>C, NM_001171625.1:c.-2595A>C, NM_001171626.1:c.-2595A>C, NM_001171627.1:c.-2595A>C, NM_001171628.1:c.-2595A>C, NM_001171629.1:c.-2595A>C, NM_001171630.1:c.-2595A>C, NM_001204384.1:c.-2595A>C, NM_001204385.1:c.-2055A>C, NM_001317010.1:c.-2595A>C, NM_003376.5:c.-2055A>C, rs1310065, rs36208051, rs61399354
A > C
SNP
No VIP available No Clinical Annotations available VA
rs714368 NC_000006.11:g.110778128T>C, NC_000006.12:g.110456925T>C, NM_033125.3:c.146A>G, NP_149116.2:p.His49Arg, XM_005267183.1:c.146A>G, XM_005267184.1:c.-3A>G, XM_005267184.2:c.-3A>G, XM_005267185.1:c.-317A>G, XM_011536204.1:c.17A>G, XM_011536205.1:c.146A>G, XM_011536206.1:c.146A>G, XM_011536207.1:c.154A>G, XM_011536208.1:c.118A>G, XM_011536209.1:c.103A>G, XM_011536210.1:c.146A>G, XM_011536211.1:c.146A>G, XM_011536212.1:c.-427A>G, XP_005267240.1:p.His49Arg, XP_011534506.1:p.His6Arg, XP_011534507.1:p.His49Arg, XP_011534508.1:p.His49Arg, XP_011534509.1:p.Ile52Val, XP_011534510.1:p.Ile40Val, XP_011534511.1:p.Ile35Val, XP_011534512.1:p.His49Arg, XP_011534513.1:p.His49Arg, rs117158242, rs52825948, rs60832844
T > C
SNP
H49R
No VIP available CA VA
rs723685 NC_000006.11:g.110763875A>G, NC_000006.12:g.110442672A>G, NM_033125.3:c.755T>C, NP_149116.2:p.Val252Ala, XM_005267183.1:c.659T>C, XM_005267184.1:c.245T>C, XM_005267184.2:c.245T>C, XM_005267185.1:c.293T>C, XM_011536204.1:c.626T>C, XM_011536205.1:c.755T>C, XM_011536206.1:c.473T>C, XM_011536207.1:c.401T>C, XM_011536208.1:c.365T>C, XM_011536209.1:c.350T>C, XM_011536210.1:c.755T>C, XM_011536211.1:c.275T>C, XM_011536212.1:c.65T>C, XP_005267240.1:p.Val220Ala, XP_005267241.1:p.Val82Ala, XP_005267242.1:p.Val98Ala, XP_011534506.1:p.Val209Ala, XP_011534507.1:p.Val252Ala, XP_011534508.1:p.Val158Ala, XP_011534509.1:p.Val134Ala, XP_011534510.1:p.Val122Ala, XP_011534511.1:p.Val117Ala, XP_011534512.1:p.Val252Ala, XP_011534513.1:p.Val92Ala, XP_011534514.1:p.Val22Ala, rs52815010, rs59277963
A > G
SNP
V252A
No VIP available CA VA
rs7254579 NC_000019.10:g.40988986T>C, NC_000019.9:g.41494891T>C, NG_007929.1:g.2688T>C, rs12721651, rs61045078
T > C
SNP
No VIP available No Clinical Annotations available VA
rs7483 NC_000001.10:g.110279701C>T, NC_000001.11:g.109737079C>T, NM_000849.4:c.670G>A, NP_000840.2:p.Val224Ile, NR_024537.1:n.904G>A, XM_011541296.1:c.889G>A, XP_011539598.1:p.Val297Ile, rs17845187, rs17857997, rs3167664, rs386610559, rs52802282, rs58618587
C > -
C > T
SNP
V224I
No VIP available No Clinical Annotations available VA
rs776746 NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770
C > T
SNP
No VIP available No Clinical Annotations available VA
rs7853758 NC_000009.11:g.86900926G>A, NC_000009.12:g.84286011G>A, NM_001199633.1:c.1381C>T, NM_022127.2:c.1381C>T, NP_001186562.1:p.Leu461=, NP_071410.1:p.Leu461=, NR_037638.2:n.1703C>T, XM_011518905.1:c.1465C>T, XM_011518906.1:c.1465C>T, XM_011518907.1:c.1132C>T, XM_011518908.1:c.742C>T, XP_011517207.1:p.Leu489=, XP_011517208.1:p.Leu489=, XP_011517209.1:p.Leu378=, XP_011517210.1:p.Leu248=, XR_929832.1:n.1572C>T, XR_930033.1:n.88-3031G>A, rs59483082, rs59559753
G > A
SNP
L461L
No VIP available CA VA
rs79085477 NC_000020.10:g.55701215C>T, NC_000020.11:g.57126159C>T, XR_936901.1:n.278+5836G>A, XR_936902.1:n.89+350G>A, XR_936903.1:n.48+399G>A, XR_936904.1:n.278+5836G>A
C > T
SNP
No VIP available No Clinical Annotations available VA
rs7911488 NC_000010.10:g.105154089A>G, NC_000010.11:g.103394332A>G, NM_001206426.1:c.-9-1866T>C, NM_001206427.1:c.-10+1414T>C, NM_032747.3:c.-143T>C, NR_031707.1:n.70T>C
A > -
A > G
SNP
No VIP available No Clinical Annotations available VA
rs7995976 NC_000013.10:g.28941060A>C, NC_000013.11:g.28366923A>C, NG_012003.1:g.133206T>G, NM_002019.4:c.2117-9238T>G, rs61179897, rs9513092
A > C
SNP
No VIP available CA VA
rs80223967 NC_000001.10:g.213943679A>G, NC_000001.11:g.213770336A>G, XR_922586.1:n.137-24048A>G, XR_922587.1:n.136+38778A>G
A > G
SNP
No VIP available No Clinical Annotations available VA
rs8110536 NC_000019.10:g.756985T>G, NC_000019.9:g.756985T>G, NM_173481.2:c.39T>G, NP_775752.1:p.Pro13=, XM_005259493.1:c.39T>G, XM_011527685.1:c.39T>G, XM_011527686.1:c.39T>G, XP_005259550.1:p.Pro13=, XP_011525987.1:p.Pro13=, XP_011525988.1:p.Pro13=, rs12979335, rs17762604, rs60374394
T > G
SNP
P13P
No VIP available No Clinical Annotations available VA
rs8187710 NC_000010.10:g.101611294G>A, NC_000010.11:g.99851537G>A, NG_011798.1:g.73832G>A, NM_000392.4:c.4544G>A, NP_000383.1:p.Cys1515Tyr, XM_005269536.1:c.4265G>A, XM_006717630.2:c.3848G>A, XP_005269593.1:p.Cys1422Tyr, XP_006717693.1:p.Cys1283Tyr, XR_945605.1:n.4608G>A, rs17222568, rs52804507, rs58135906
G > A
SNP
C1515Y
No VIP available No Clinical Annotations available VA
rs8187996 NC_000009.11:g.75516495C>T, NC_000009.12:g.72901579C>T, NG_012249.1:g.56475G>A, NM_000689.4:c.1434-299G>A, XM_005251800.1:c.1434-299G>A, XM_005251801.1:c.1374-299G>A, rs17647529
C > T
SNP
No VIP available CA VA
rs8192709 NC_000019.10:g.40991369C>T, NC_000019.9:g.41497274C>T, NG_007929.1:g.5071C>T, NM_000767.4:c.64C>T, NP_000758.1:p.Arg22Cys, XM_005258569.1:c.64C>T, XM_005258569.3:c.64C>T, XM_005258570.1:c.64C>T, XM_006723050.2:c.64C>T, XM_011526546.1:c.64C>T, XM_011526547.1:c.64C>T, XM_011526548.1:c.64C>T, XP_005258626.1:p.Arg22Cys, XP_005258627.1:p.Arg22Cys, XP_006723113.1:p.Arg22Cys, XP_011524848.1:p.Arg22Cys, XP_011524849.1:p.Arg22Cys, XP_011524850.1:p.Arg22Cys
C > T
SNP
R22C
No VIP available No Clinical Annotations available VA
rs833058 NC_000006.11:g.43731854C>T, NC_000006.12:g.43764117C>T, rs58522910
C > T
SNP
No VIP available No Clinical Annotations available VA
rs903880 NC_000016.10:g.16036657C>A, NC_000016.9:g.16130514C>A, NG_028268.1:g.92081C>A, NM_004996.3:c.809+54C>A, NT_187607.1:g.1694556C>A, XM_005255326.1:c.809+54C>A, XM_005255327.1:c.683+54C>A, XM_005255328.1:c.671+54C>A, XM_005255329.1:c.809+54C>A, XM_011522497.1:c.785+54C>A, XM_011522498.1:c.863+54C>A, rs58300570
C > A
SNP
No VIP available No Clinical Annotations available VA
rs9501929 NC_000006.11:g.3157854T>C, NC_000006.12:g.3157620T>C, NG_042223.1:g.4930A>G, NM_001069.2:c.-157A>G, NM_001310315.1:c.-544A>G, XM_005249359.1:c.-544A>G, XR_926395.1:n.-56T>C
T > C
SNP
No VIP available CA VA
rs9561778 NC_000013.10:g.95713715G>T, NC_000013.11:g.95061461G>T, NM_001301829.1:c.3225+1243C>A, NM_005845.4:c.3366+1243C>A, XM_005254025.1:c.3237+1243C>A, XM_005254025.2:c.3237+1243C>A, XM_005254026.1:c.3225+1243C>A, XM_005254027.1:c.3141+1243C>A, XM_006719914.1:c.3276+1243C>A, XM_011521047.1:c.2817+1243C>A, rs17234943
G > A
G > T
SNP
No VIP available No Clinical Annotations available VA
rs9611280 NC_000022.10:g.40552119G>A, NC_000022.11:g.40156115G>A, NM_001024843.1:c.46G>A, NP_001020014.1:p.Val16Met, XM_005261393.1:c.46G>A, XM_005261394.1:c.46G>A, XP_005261450.1:p.Val16Met, XP_005261451.1:p.Val16Met, rs52808489, rs61442552
G > A
SNP
V16M
No VIP available No Clinical Annotations available VA
rs9908694 NC_000017.10:g.37997772C>T, NC_000017.11:g.39841519C>T, NG_029104.2:g.27670G>A, NM_001257408.1:c.8-9368G>A, NM_001257409.1:c.8-9368G>A, NM_001257410.1:c.8-9368G>A, NM_001257411.1:c.8-9368G>A, NM_001257412.1:c.8-9368G>A, NM_001257413.1:c.8-9368G>A, NM_001257414.1:c.8-9368G>A, NM_001284514.1:c.-860-9368G>A, NM_001284515.1:c.-692-9368G>A, NM_012481.4:c.8-9368G>A, NM_183228.2:c.8-9368G>A, NM_183229.2:c.8-9368G>A, NM_183230.2:c.8-9368G>A, NM_183231.2:c.8-9368G>A, NM_183232.2:c.8-9368G>A, NR_047559.1:n.70-9368G>A, NR_047560.1:n.70-9368G>A, rs61312250
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • cyclophosphamide
Trade Names
  • ASTA
  • Asta B 518
  • CP
  • CPA
  • CTX
  • CY
  • Clafen
  • Claphene
  • Cyclophosphamid
  • Cyclophosphamide Monohydrate
  • Cyclophosphamide Sterile
  • Cyclophosphamidum
  • Cyclophosphan
  • Cyclophosphane
  • Cyclophosphoramide
  • Cyclostin
  • Cyklofosfamid
  • Cytophosphan
  • Cytoxan
  • Cytoxan Lyoph
  • Endoxan
  • Endoxan R
  • Endoxan-Asta
  • Endoxana
  • Endoxanal
  • Endoxane
  • Enduxan
  • Genoxal
  • Hexadrin
  • Lyophilized Cytoxan
  • Mitoxan
  • Neosar
  • Procytox
  • Rcra Waste Number U058
  • Revimmune
  • Semdoxan
  • Sendoxan
  • Senduxan
  • Zyklophosphamid
Brand Mixture Names
  • Procytox for Injection 2000mg Pws Iv (Cyclophosphamide + Sodium Chloride)

PharmGKB Accession Id

PA449165

Type(s):

Prodrug

Description

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Source: Drug Bank

Indication

For management of malignant lymphomas, multiple myeloma,leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma and carcinoma of the breast

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

Source: Drug Bank

Pharmacology

Cyclophosphamide is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.

Source: Drug Bank

Food Interaction

Take with food to reduce irritation.|Drink liberally- 2 to 3 liters/day.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

hepatic

Source: Drug Bank

Protein Binding

>60%

Source: Drug Bank

Absorption

90-100%

Source: Drug Bank

Half-Life

3-12 hours

Source: Drug Bank

Toxicity

infection, myelosuppression, and cardiac toxicity

Source: Drug Bank

Route of Elimination

It is eliminated primarily in the form of metabolites, but from 5% to 25% of the dose is excreted in urine as unchanged drug.

Source: Drug Bank

Chemical Properties

Chemical Formula

C7H15Cl2N2O2P

Source: Drug Bank

Canonical SMILES

ClCCN(CCCl)P1(=O)NCCCO1

Source: Drug Bank

Average Molecular Weight

261.086

Source: Drug Bank

Monoisotopic Molecular Weight

260.02481966

Source: Drug Bank

SMILES

ClCCN(CCCl)P1(=O)NCCCO1

Source: Drug Bank

InChI String

InChI=1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Cyclophosphamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of cyclophosphamide.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA10
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA12
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA13
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA7
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA8
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCA9
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCB1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB10
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB11
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB7
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB8
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCB9
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ABCC1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCC10
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCC11
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCC12
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCC13
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ABCC2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCC3
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCC4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCC5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCC6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCC8
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCC9
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCD1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCD2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCD3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCD4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCE1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCF1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCF2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCF3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCG1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCG2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCG4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCG5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABCG8
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ABL1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ADH1C
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADM
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADSL
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
AGO1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ALDH1A1
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ALDH3A1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ALPL
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
APOB
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ASNS
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
BCL2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
BCL2L11
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
BCR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
BGLAP
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
BMP7
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
C18orf56
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
C5orf22
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CBR3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CCND1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CD27
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CDK1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CDKN1A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CFTR
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CNOT1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CNTNAP2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CRHR1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CTNNB1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CXCL12
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CXCL13
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CXCL8
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CXCR2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYBA
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP19A1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP1A1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP1A2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP1B1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2A13
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
CYP2A6
CYP2B6
CYP2C19
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
CYP2C8
CYP2C9
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2D6
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2E1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2W1
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP3A
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
CYP3A4
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
CYP3A5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DARS
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
DDX20
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DHFR
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
DOK5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
DRD2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
DROSHA
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
DUX1
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
EGLN3
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
EPAS1
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
EPHA6
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
EPHX1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ERBB2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ERCC1
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ERCC2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ERCC4
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ERCC5
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
FCGR2A
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
FCGR3A
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
FGFR4
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
FLT1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
FOLH1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GATA3
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
GEMIN4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GGH
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GMPS
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GRIA1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GSTA1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GSTA2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GSTM1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GSTM3
GSTP1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GSTT1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HDAC4
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HPRT1
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
IKZF3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
IL10
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
IL6
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
IMPDH1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ITPA
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
KLC3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
LEPR
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
LIG3
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
LINC00251
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MAPT
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MGST3
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MIR1206
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MIR1307
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MIR146A
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MIR2053
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MIR300
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MIR423
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MIR449B
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MIR492
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MIR577
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MIR604
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MIR618
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
MISP
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
MTHFD1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
MTHFR
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
MTR
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
MUTYH
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
NAT2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NCF4
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
NOS3
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NQO1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
NQO2
NR1I2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NR1I3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NR3C1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
NTAN1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PACSIN2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
POR
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
RAC2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
RAD52
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SERPINE1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SHMT1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC12A3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC19A1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SLC22A16
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC28A2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLC28A3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC29A1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC29A2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLC5A5
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SLCO1A2
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SLCO1B1
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SOD2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SPIDR
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SULT1A1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SULT1A3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
TAP1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
TAP2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
TNFRSF8
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
TNRC6A
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
TNRC6B
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
TP53
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
TPMT
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
TUBB2A
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
TWIST2
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
TYMS
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT1A1
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
UGT2B17
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
VDR
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VEGFA
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
WDR7
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
XDH
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
XPO5
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
XRCC1

Drug Interactions

Interaction Description
digoxin - cyclophosphamide The antineoplasic agent decreases the effect of digoxin (source: Drug Bank)
digoxin - cyclophosphamide The antineoplasic agent decreases the effect of digoxin (source: Drug Bank)
fluconazole - cyclophosphamide Reduces metabolism and clearance of cyclophosphamide (source: Drug Bank)
fluconazole - cyclophosphamide Reduces metabolism and clearance of cyclophosphamide (source: Drug Bank)
thiotepa - cyclophosphamide Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Cyclophosphamide, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Cyclophosphamide if Thiotepa is initiated, discontinued or dose changed. (source: Drug Bank)
trastuzumab - cyclophosphamide Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to cyclophosphamide: 102

No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Dual role of the CXCL12 polymorphism in patients with chronic lymphocytic leukemia. HLA. 2016. Butrym A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. Pharmacogenomics. 2016. Schirmer Jan Henrik, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma. European journal of cancer (Oxford, England : 1990). 2016. Veal Gareth J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study. BMC cancer. 2016. Reimer Toralf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. International journal of cancer. Journal international du cancer. 2015. Hein Alexander, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood. 2015. Karol Seth E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese systemic lupus erythematosus patients. British journal of clinical pharmacology. 2015. Shu Wenying, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients. Clinical immunology (Orlando, Fla.). 2015. Wang Hong-Na, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment. Leukemia research. 2015. Butrym Aleksandra, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predictive value of cytokines and immune activation biomarkers in AIDS-related non-Hodgkin lymphoma treated with rituximab plus infusional EPOCH (AMC-034 trial). Clinical cancer research : an official journal of the American Association for Cancer Research. 2015. Epeldegui Marta, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship of MTHFR and NQO1 Pharmacogenetics and Chemotherapy Clinical Outcomes in Breast Cancer Patients. Biochemical genetics. 2015. Chaturvedi Pankaj, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. Haematologica. 2015. Jordheim Lars P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. British journal of clinical pharmacology. 2015. Assouline Sarit, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy. Drug metabolism and pharmacokinetics. 2015. Ikeda Midori, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial. The pharmacogenomics journal. 2015. Le Morvan V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. Cancer. 2014. Derosa Lisa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission. Case reports in oncological medicine. 2015. Fuentes Alejandra C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer. International journal of clinical and experimental pathology. 2015. Shao Xiying, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma. Pharmacogenomics. 2015. Reichwagen Annegret, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The CYP19 RS4646 Polymorphism IS Related to the Prognosis of Stage I-II and Operable Stage III Breast Cancer. PloS one. 2015. Shao Xiying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014. Lopez-Lopez Elixabet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clinical pharmacology and therapeutics. 2014. Pinto N, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. Abraham Jean E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics. 2014. Khrunin Andrey V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. Blood. 2013. Johnson Gillian G, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-Fluorouracil combination chemotherapy. PloS one. 2014. Geng Ruixuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia. PloS one. 2014. López-López Elixabet, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nature genetics. 2013. Perez-Andreu Virginia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. The pharmacogenomics journal. 2013. Yao S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. British journal of cancer. 2013. Orlandi P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study. Cancer causes & control : CCC. 2013. Brooks Jennifer D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The expression profile of ATP-binding cassette transporter genes in breast carcinoma. Pharmacogenomics. 2013. Hlaváč Viktor, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy. Pharmacogenetics and genomics. 2012. Hu Lei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: very important pharmacogene information for GSTT1. Pharmacogenetics and genomics. 2012. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast cancer research and treatment. 2012. Hertz Daniel L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy. Pharmacogenomics. 2012. Yan Li, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomic approach towards personalized anticancer drug therapy. Pharmacogenomics. 2012. Midorikawa Yutaka, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics. 2012. Khrunin Andrey, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and genomics. 2011. Jamieson David, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood. 2011. Ahlgrimm Manfred, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenetics and genomics. 2011. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 Polymorphisms and their Relationship with Premature Ovarian Failure in Premenopausal Women with Breast Cancer Receiving Doxorubicin and Cyclophosphamide. The breast journal. 2011. Wessels Alette M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2011. Tamura K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of polymorphisms in MTHFR 677 C¿T, TYMS 3R¿2R and MTR 2756 A¿G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC. Pharmacogenomics. 2011. Cui Lian-Hua, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature genetics. 2011. Yang Jun J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Copy number variants in pharmacogenetic genes. Trends in molecular medicine. 2011. He Yijing, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chinese medical journal. 2011. Zhang Bai-Lin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PloS one. 2011. Caronia Daniela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010. Costa R B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer epidemiology. 2010. Henríquez-Hernández Luis Alberto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer chemotherapy and pharmacology. 2010. Harmsen Stefan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertility and sterility. 2010. Su H Irene, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 2C9-CYP2C9. Pharmacogenetics and genomics. 2010. Van Booven Derek, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus. Rheumatology international. 2010. Ngamjanyaporn Pintip, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British journal of cancer. 2010. Bray J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. The pharmacogenomics journal. 2010. Khrunin A V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Human genetics. 2010. Rodriguez-Antona Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast cancer research : BCR. 2010. Gor Priya P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genetics and molecular research : GMR. 2010. Oliveira A L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. Journal of human genetics. 2009. Low Siew-Kee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Current drug metabolism. 2009. Di Yuan Ming, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Current drug metabolism. 2009. Mo Sui-Lin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Choi Ji-Yeob, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer chemotherapy and pharmacology. 2009. Kim Jong Gwang, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Glynn Sharon A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2009. Rossi D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer. Cancer research. 2009. DeMichele Angela, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. The Journal of pediatrics. 2009. Patiño-García Ana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2009. Rocha V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008. Schultheis Anne M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenetics and genomics. 2008. Ekhart Corine, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy. Journal of cancer research and clinical oncology. 2008. Huang Zhao-Hui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Current drug metabolism. 2008. Wang Hongbing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nature genetics. 2008. Fagerholm Rainer, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP450 pharmacogenetics for personalizing cancer therapy. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2008. van Schaik Ron H N. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenetics and genomics. 2008. Ekhart Corine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. British journal of cancer. 2008. Helsby N A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. The Journal of pharmacology and experimental therapeutics. 2008. Hofmann Marco H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clinical pharmacology and therapeutics. 2007. Myers R M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacology & therapeutics. 2007. Ingelman-Sundberg Magnus, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors. Clinical pharmacology and therapeutics. 2007. Bouligand J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HER2 and response to paclitaxel in node-positive breast cancer. The New England journal of medicine. 2007. Hayes Daniel F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. The pharmacogenomics journal. 2007. Marsh S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. The Journal of pharmacology and experimental therapeutics. 2007. Faucette Stephanie R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Molecular cancer therapeutics. 2006. Morel Alain, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomic signatures to guide the use of chemotherapeutics. Nature medicine. 2006. Potti Anil, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006. Thussbas Christoph, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Investigational new drugs. 2005. van Schaik Ron H N. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. The pharmacogenomics journal. 2005. Timm R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis and rheumatism. 2004. Takada Kazuki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. Robien Kim, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Cancer. 2003. Yang Wentao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. International journal of cancer. Journal international du cancer. 2003. Sweeney Carol, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine. 2001. Slamon D J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug metabolism and disposition: the biological fate of chemicals. 1997. Code E L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997. Chang T K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer research. 1994. Dirven H A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer research. 1993. Chang T K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rapid development of enhanced clearance after high-dose cyclophosphamide. Clinical pharmacology and therapeutics. 1988. Moore M J, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0054-4129-25
DrugBank:
DB00531
ChEBI:
4027
KEGG Drug:
D00287
PubChem Compound:
2907
PubChem Substance:
148529
46505441
Drugs Product Database (DPD):
2241797
ChemSpider:
2804
Therapeutic Targets Database:
DAP000532
FDA Drug Label at DailyMed:
1bd19d11-477e-4b4d-8d1d-4b376a403140
367b47d7-c4de-4b39-bd3a-69c29d80396f

Clinical Trials

These are trials that mention cyclophosphamide and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.